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Abstract 
A mutant HIV-1 Tat protein termed Nullbasic has a strong antiviral activity via three 
independent mechanisms that disrupts; 1) reverse transcription of the viral RNA genome 
into a DNA copy, 2) HIV-1 Rev protein function required for unspliced and singly spliced 
viral mRNA transport from the nucleus and 3) HIV-1 transcription by RNA Polymerase II.  
The Nullbasic protein is derived from the HIV-1 subtype B strain BH10 and has only been 
tested against other HIV-1 subtype B strains. Using a gammaretroviral vector as a gene 
delivery system, fusion forms of Nullbasic, Nullbasic-mCherry and Nullbasic-ZSGreen1, 
were tested against representative HIV-1 strains from subtypes C, D and A/D recombinant 
to determine if it can inhibit their replication. The results show that Nullbasic-mCherry inhibits 
Tat-mediated transactivation and virus replication of all the HIV-1 strains tested in TZM-bl 
cells. Importantly, Nullbasic-ZSGreen1 inhibits replication of the HIV-1 strains in primary 
CD4+ T cells without affecting cell proliferation, cytotoxicity or level of apoptotic cells. 
However, long-term expression of Nullbasic protein in the cells is required to provide a 
strong and durable antiviral activity.  
Nullbasic antiviral activity in vivo has not been studied. Therefore, a humanized mouse 
model was established to test Nullbasic antiviral activity in vivo. This animal model harbors 
human CD4+ T cells for a short period, and is therefore suitable for testing Nullbasic antiviral 
activity against an acute HIV-1 infection. The results also indicate that Nullbasic-ZSGreen1 
inhibits HIV-1 replication in vivo.  
Gene delivery to target cells using gammaretroviral system may raise safety concerns due 
to its oncogonic potential. Therefore, a safer and better vector, a lentiviral vector, was 
optimized to deliver Nullbasic to T cells. However, Nullbasic delivery to T cells using a 
lentiviral system was problematic because Nullbasic itself inhibits lentivirus replication. 
Therefore, we optimized the nullbasic delivery method by using viral and cellular proteins 
antagonistic to Nullbasic. Transduction efficiency of Jurkat T cells by Nullbasic lentiviral VLP 
was optimal when addition of Tat and DDX1 in combination with spinoculation method was 
used. Nevertheless, this method did not improve transduction of primary CD4+ T cells by 
Nullbasic lentiviral VLP. 
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Overall, Nullbasic has antiviral activity against all strains from the HIV-1 tested in vitro and 
inhibits acute HIV-1 infection in vivo. Therefore, Nullbasic may have utility in a future gene 
therapy approach. 
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CHAPTER 1  
Introduction 
 
 
This introductory chapter gives an overview of the main points of this thesis. This chapter is 
presented in five sections, firstly the background of the study, secondly rationale of 
investigations, thirdly hypothesis followed by aims and finally the study approaches. 
1.1 Background  
Human immunodeficiency virus type 1 (HIV-1) infection remains one of the most serious 
health problems. Globally, 36.7 million people were living with HIV-1 by the end of 2015 and 
1.2 million people died per annum from acquired immunodeficiency syndrome (AIDS)-
related causes4. Whilst current combined antiretroviral therapy (cART) as recommended by 
World Health Organization (WHO) is capable of controlling the disease by delaying the 
disease progression and spread, lack of a cure and drug adverse effects remain as 
problems.  Antiretroviral therapy using multi-drug regimens is costly and has potential side 
effects with long term use. Adverse events following long term use of cART that have been 
reported include brain aging (50%), gastrointestinal effects including nausea, vomiting and 
diarrhea (28%), lipodystrophy, hyperlipidemia and hypercholesterolemia (3-5%), 
hyperglycemia (0.47%) and hepatotoxicity (25.5%)5-10. These adverse effects lead to low 
adherence to cART6.  Also, the potency of cART can be hindered by viral mutations that 
lead to HIV-1 quasispecies diversity and result in different drug susceptibilities. The 
combined effects caused by poor adherence and viral mutations induce development of 
drug resistance11. Furthermore, although cART is able to suppress viral load, once the 
medication is discontinued, HIV reappears in plasma. HIV-1 vaccine developments are 
hindered by the huge genetic variation in HIV-1 strains12. Therefore, a novel approach to 
controlling this disease, such as gene therapy, is required. Unlike antiretroviral therapy, 
which requires repeated doses, gene therapy offers a one-shot-treatment over a lifetime. 
This thesis focuses on the development of a novel gene therapy approach targeting HIV-1 
replication. 
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Because HIV-1 can develop drug resistance, understanding the virus and its life cycle is 
crucial to finding an agent that can target multiple steps of viral replication. The literature 
review in Chapter 2 discusses HIV-1 morphology and genomic structure as well as its life 
cycle. The spread of HIV-1 subtypes is also addressed. Current gene therapy approaches 
that have undergone pre-clinical or clinical trial in various stages are highlighted.  The use 
of murine models to test the new potential gene therapies is also discussed. 
A novel gene therapy agent called Nullbasic has shown strong antiviral activity against HIV-
1 infection in vitro. Nullbasic is a transdominant negative mutant of Tat, a small viral 
regulatory protein that is critical for enhancing the HIV-1 transcription efficiency from the 
long terminal repeat (LTR) transcriptional promoter13.  Detailed explanation about Tat roles 
are reviewed in Chapter 2. Nullbasic has the ability to inhibit HIV-1 at three steps during viral 
replication, unlike other molecular therapeutics, which inhibit a single viral target.  Nullbasic’s 
three antiviral mechanisms provide a strong incentive to investigate the development of 
Nullbasic as a potential future therapy for HIV-1.  Because Nullbasic interferes with HIV-1 
infection in multiple ways, Nullbasic therapy may reduce the risk of the virus developing 
resistance, thus maximizing the potential for treatment efficacy. 
In earlier research, Nullbasic showed strong inhibition of HIV-1 subtype B strains replication 
in vitro in Jurkat cells and in primary CD4+ T cells, indicating this protein may be useful as 
an antiviral agent in preventing HIV-1 infection14,15.  Nullbasic interferes with HIV-1 
replication by targeting three steps of HIV-1 life cycle, including Tat-mediated 
transactivation, reverse transcription and Rev-mediated transport HIV-1 mRNA15,16. 
Nullbasic inhibits HIV-1 transcription by obstructing Tat interaction with positive transcription 
elongation factor (P-TEFb). This transdominant negative protein acts as a competitive agent 
against wild type Tat by binding to Cyclin-dependent kinase 9 (CDK9), part of P-TEFb 
complex that plays a role in RNA polymerase II phosphorylation during early 
transcription15,17. In addition, Nullbasic can alter the HIV-1 LTR epigenetic state so that it 
inhibits the binding of TAR, located at the 5’ end of HIV-1 LTR promoter, to RNA polymerase 
II2.  Nullbasic also interferes with Rev nucleocytoplasmic transport activity and thereby 
disrupts the Rev nucleolar organisation and functions16.  As a consequence, Nullbasic 
downregulates the expression of unspliced and singly-spliced HIV-1 mRNAs and therefore 
inhibits virus replication15. The other antiviral mechanism of Nullbasic is achieved by 
targeting the reverse transcription complex. Nullbasic binds to reverse transcriptase and 
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accelerates viral uncoating, leading to disruption of reverse transcriptase complex18.  Details 
of Nullbasic antiviral mechanisms are reviewed in Chapter 2. 
In this thesis, we observed that Nullbasic can inhibit different HIV-1 strains from different 
subtypes, as discussed in Chapter 3. Therefore, Nullbasic also has a potential to be 
developed as an antiviral agent against HIV-1 subtypes other than subtype B. Furthermore, 
in Chapter 4, an HIV-1 acute infection model development in BALB/c-Rag2-/-γc-/- mice is 
explained. The human CD4+ T cells were engrafted in the mice and HIV-1 viremia was 
detected in a limited period. In Chapter 5, we reveal that addition and combination of 
Nullbasic antagonist proteins can overcome Nullbasic inhibition to a lentiviral vector used to 
deliver the nullbasic gene to Jurkat cells. However, lentiviral based nullbasic transduction 
on primary CD4+ T cells was not improved; thus, further study is required to optimize 
transduction efficiency of lentiviral vector to deliver nullbasic.  These notable results and the 
combined conclusions from this thesis as well as the limitation of this study are discussed 
in Chapter 6. This includes the future development of Nullbasic for HIV-1 research and 
therapy.  
1.2 Rationale of investigations 
The Nullbasic protein is derived from HIV-1 subtype B Tat and has been extensively studied 
in vitro against HIV-1 subtype B, but the antiviral activity of Nullbasic against other HIV-1 
subtypes has not been studied.  The genome changes between different subtypes may 
result in amino acid substitutions in viral proteins, including Tat. The sequence variation of 
Tat between subtypes may influence its interaction with RNA and cellular proteins, which 
may affect Nullbasic antiviral activity. Hence, it is important to investigate Nullbasic antiviral 
activity against different subtypes of HIV-1 to determine if Nullbasic can also inhibit 
replication of diverse HIV-1 subtypes and provide a broad coverage therapy.  
HIV-1 subtype B, commonly found in Europe and US, accounts for only ~10% of HIV 
infection worldwide, while other subtypes such as subtype C, mainly found in developing 
regions such as in Sub-Saharan Africa, India and South America, is responsible for ~50% 
of HIV infection worldwide19. Subtypes D and A/D are also spreading rapidly in Sub-Saharan 
Africa20. Details of these HIV-1 subtype variations are reviewed in Chapter 2. Chapter 3 
elucidates Nullbasic antiviral activity in vitro against HIV-1 strains representative of subtype 
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B, C, D and AD. The investigation of Nullbasic antiviral activity against different strains 
representing diverse HIV-1 subtypes in primary CD4+ T cells provides evidence that 
Nullbasic can be promising as an antiviral agent for different HIV-1 strains. 
So far, Nullbasic efficacy and antiviral mechanism against HIV-1 subtype B strains has been 
extensively studied in vitro. However, the protection of Nullbasic against HIV-1 infection in 
vivo has not been studied. A preclinical study to observe the effect of Nullbasic against HIV-
1 replication in vivo is required before it goes further into clinical trial. An animal model is 
useful in studying the HIV-1 pathology and reservoir.  Therefore, an acute HIV-1 infected 
mouse model was established to study Nullbasic antiviral activity against acute HIV-1 
infection in vivo, and this will be described in Chapter 4. The Nullbasic expressing cells are 
engrafted in the chosen mouse model in a short period and enables in vivo testing of 
Nullbasic activity against acute HIV-1 infection.  
Nullbasic gene has been delivered to target cells using a gammaretroviral vector. However, 
there may be an oncogenic risk from retroviral vectors due to insertional mutagenesis. 
Lentiviral vectors are known to be safer than retroviral vectors and provides stable transgene 
expression in the target cells. Lentiviral vectors can transduce non-dividing cells and 
therefore are more promising for transgene delivery to primary cells.  
Previous research studied the delivery of the nullbasic gene using a lentiviral vector, but the 
transduction efficiency of the target cells was low due to reverse transcriptase inhibition by 
Nullbasic proteins14,21 and thus, transduction optimization is required. Nullbasic disrupts 
reverse transcription by direct binding to reverse transcriptase and leads to defective 
reverse transcription complex18.  Rev, a viral protein that is required for transporting viral 
mRNA from nucleus to cytoplasm, is also inhibited by Nullbasic. The Nullbasic inhibition to 
Rev is indirect by binding to a cellular factor required for Rev activity named DDX1 (DEAD 
helicase box protein 1)3. The majority of lentiviral systems used to deliver genes to target 
cells are HIV-1 based vectors, therefore, Nullbasic can inhibit these vectors. 
To improve the transduction efficiency of Nullbasic lentiviral system in T cells, we introduced 
an intrabody protein termed hu-Tat2, a synthetic intracellular antibody expressed within the 
cytoplasm22. The Nullbasic and Tat protein sequences are conserved except for the basic 
region. The hu-Tat2 intrabody protein can bind Tat amino acids 1 to 19, a proline rich region 
that is conserved in Nullbasic23, and therefore it can prevent the Nullbasic effect on reverse 
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transcription. Furthermore, overexpression of Tat was found able to reverse the inhibitory 
activity of Nullbasic towards lentiviral vector. Chapter 5 in this thesis discusses the use of 
the use of Nullbasic antagonists to improve transduction efficiency of lentivirus in conveying 
Nullbasic to T cells. It was observed that the coexpression of cellular and viral proteins 
antagonists of Nullbasic in lentivirus producer cells could improve the efficiency of Nullbasic 
lentiviral virus like particle (VLP)-mediated transduction of Jurkat cells, but not primary cells. 
1.3 Hypothesis 
The hypothesis of this study is: 
Long term expression of Nullbasic in human CD4+ T cells protects them from HIV-1 
replication by a variety of strains both in vitro and in vivo. 
1.4 Objectives 
The hypothesis above is addressed by the specific objectives of this study, which are: 
1. to determine if Nullbasic can inhibit replication of diverse HIV-1 strains representing 
different subtypes in vitro; 
2. to establish an acute mouse model and investigate Nullbasic effects in vivo against 
acute HIV-1 infection. 
3. to optimize the production and transduction efficiency of Nullbasic lentiviral VLP for 
T cells. 
1.5 Study approaches 
In order to prove the hypothesis, those three aims above were addressed by conducting the 
following study approaches: 
Aim 1: to determine if Nullbasic can inhibit replication of diverse HIV-1 strains representing 
different subtypes in vitro 
This aim is elucidated in chapter 3. We evaluated Nullbasic antiviral activity on TZM-bl cell 
lines and primary CD4+ T cells. Four HIV-1 strains from different subtypes were chosen: 
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HIV-1NL4-3 (subtype B), HIV-1ZAC (subtype C), HIV-1MAL (subtype D) and HIV-1ELI (subtype 
A/D recombinant). Firstly, we established TZM-bl cell lines expressing Nullbasic-mCherry 
(NB-mCh) and mCherry (mCh) by transduction and fluorescence activated cell sorting 
(FACS) selection. Then, by transfecting these cell lines with Tat expression vectors, we 
investigated if Nullbasic can inhibit transactivation by Tat from different HIV-1 strains. Using 
the same cell lines, we also performed infection assay to determine if Nullbasic can inhibit 
transactivation of the HIV-1 LTR from different HIV-1 strains.  
Nullbasic inhibition on replication of the HIV-1 strains chosen was examined in the TZM-bl 
cell lines as well as in primary CD4+ T cells using a different fluorescent fusion protein 
attached to Nullbasic called ZSGreen1 (NB-ZSG1). Using NB-ZSG1 fusion protein, 
Nullbasic antiviral activity against HIV-1 strains from different subtypes in primary CD4+ T 
cells was revealed. We also monitor Nullbasic protein levels of expression by flow cytometry. 
Furthermore, to confirm that there is no toxicity effect of Nullbasic expression in primary 
CD4+ T cells, we conducted an MTS, proliferation and apoptosis assays. 
Aim 2: to establish an acute mouse model and investigate Nullbasic effects in vivo against 
acute HIV-1 infection 
To achieve aim 2, a humanized mouse model was developed. BALB/c-Rag2-/-γc-/- mice 
were transplanted with NB-mCh or mCh or NB-ZSG1 or ZSG1 transduced primary CD4+ T 
cells and then challenged with HIV-1AD8. Engraftment of the human CD4+ T cells in the mice 
was measured by flow cytometry. Viral load was measured by quantitative reverse 
transcription real time PCR (qRT-PCR) from blood, spleen and lung samples. 
Aim 3: to optimize the production and transduction efficiency of Nullbasic lentiviral VLP on 
T cells 
To achieve efficient transduction of Jurkat T cell line and primary CD4+ T cells by NB-ZSG1 
lentiviral VLP, we introduced Nullbasic antagonist cellular and viral proteins. A humanized 
anti-Tat intrabody (huTat2), HIV-1 Tat and Rev, as well as DDX1 proteins were added in the 
VLP producer cells. We also combined those methods with spinoculation. The transduction 
rate was measured by flow cytometry.  
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CHAPTER 2  
Literature Review 
 
2.1  HIV-1 epidemic and current therapy 
HIV, a virus that impairs the human immune system and weakens the natural defense 
against infections, remains one of the world’s biggest health challenges. Since the first 
pandemic identified in 1981 by the US Center for Disease Control and Prevention (CDC), 
HIV has infected more than 78 million people and caused more than 35 million deaths. The 
number of people living with HIV has been steadily increasing and reached ~38.8 million at 
the end of 201524. More than 95% of HIV infections are in developing countries, with the 
highest prevalence (70%) is in sub-Saharan Africa4,25. Approximately 5700 people are 
infected every day, and 2.1 million newly infected cases were reported in 2015. Although 
the global number of AIDS related deaths has been declining steadily in the last decade, 
dropping from 1.8 million in 2005 to 1.1 million in 2015, death rates have increased in several 
developing countries such as Indonesia and the Philippines25,26.  
HIV not only makes people vulnerable to AIDS-related diseases including opportunistic 
infections and cancers, it also impacts negatively on their economic and social life. Stigma 
and discrimination towards people living with HIV threatens their access to sustainable 
employment and healthcare4. Even though cART coverage decreased AIDS-related 
mortality rate globally, the burden of disease remains high. Sustainable funding for 
HIV/AIDS interventions is required, especially in low income countries in where HIV 
prevalence is high and health resources are scarce24. 
First line cART recommended by WHO includes two nucleoside reverse transcriptase 
inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitors (NNRTIs). For 
example, the combination of efavirenz, tenofovir disoproxil fumarate and emtricitabine or 
lamivudine27,28. Second line cART consists of one or two NRTIs boosted with one protease 
inhibitors (PIs), such as lopinavir or Atazanavir27,29. Third line ART regimen includes 
integrase inhibitors such as raltegravir combined with second generations of NNRTIs such 
as etravirine and PIs such as Darunavir27,29. The most common reasons of therapy switching 
8 
 
from first line, second or third line ARTs are adverse event occurrence and virological 
treatment failure due to low adherence or drug resistance mutations30. A clinical study of 
953 HIV-1 patients in Uganda showed that 67.3% of the patients were on first line cART, 
while the rest received third line cART. However, virological treatment failure was found in 
half of the treated patients, with one fifth of the cases caused by drug resistance mutations29. 
This increased the necessity of third line cART. Subsequent studies in the US and Thailand 
observed that third line cART was well tolerated and able to supress the viral load as few 
as 50 copies/ml30,31. 
Current HIV therapies using cART have reduced plasma viremia and slow down the disease 
progression, but virus eradication or a cure has not been achieved so far. Residual viremia 
persists and may arise from the infected cells that become latent viral reservoirs. Long-term 
medication helps reduce the viral load to an undetectable level, but soon after the therapy 
is discontinued, the viral load increases and accelerates disease progression32.  Many 
adverse effects following cART administration have been reported, including gastrointestinal 
intolerance (nausea, vomiting and diarrhea), lipodystrophy, hyperlipidemia, 
hypercholesterolemia, hyperglycemia, neurotoxicity, hepatotoxicity, paresthesias, 
nephrolithiasis and skin rash5-9,33. These adverse effects reduce compliance. Furthermore, 
the high mutational rate of HIV-1 due to reverse transcription infidelity and recombination 
has created a number of HIV-1 strains that are not susceptible to cART. Non-compliance 
due to adverse effects of cART and the mutability of HIV-1 have increased drug resistance 
events. Therefore, an alternative therapy that can provide a combination of multiple antiviral 
activities without the need for lifelong medication, such as gene therapy, is required. 
HIV-1 gene therapies aim to deliver transgenes to human target cells or delete unwanted 
genes to eliminate HIV-1 infection by inhibiting virus replication, rendering cells resistant to 
HIV-1 infection or providing immunity against HIV-1 antigens34. Therefore, understanding 
the virus structure and function, life cycle and host factors, pathogenesis, delivery vectors 
and animal models is important in developing gene therapy strategies. 
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2.2 HIV-1 – The virus  
2.2.1 The basic structure of HIV-1 
An HIV virion is a spherical particle with diameter 100 nm. This virion consists of a viral 
envelope, matrix proteins (MA) and a viral core. The envelope protein consists of an external 
part, composed of glycoprotein gp120, on the surface (SU) of the virion, and a 
transmembrane (TM) part, composed of gp41 (Fig. 2-1). Both proteins are formed by 
enzymatic cleavage of gp16035,36. During viral entry to the targeted cells, gp120 plays a role 
in attaching the virus to the host cell, while gp41 is required in the cell fusion process. The 
HIV structural matrix protein, which is made from the p17 protein, lies between the envelope 
and the core. The HIV-1 core contains a 24kD capsid (CA) protein, p24, and a nucleocapsid 
protein, p7 which enclose two single strands of viral mRNA and are involved in the reverse 
transcription process36,37. This p24 protein is abundantly present in the blood serum of newly 
infected people, and therefore p24 levels are used to diagnose acute HIV-1 infection38. 
Within the core, there are the essential viral enzymes reverse transcriptase (RT), integrase 
(IN) and protease (PR)37. 
 
Figure 2-1. The basic structure of an HIV-1 virion 
A HIV-1 virion has a viral envelope composed of glycoprotein gp120 on the surface and gp41 on the 
transmembrane. Other structural proteins such as matrix and capsid are shown. Inside the capsid, 
an HIV-1 has two single-stranded viral mRNA and the enzymatic proteins reverse transcriptase, 
integrase and protease. 
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2.2.2 The structure of HIV-1 genome  
Each HIV-1 virion contains two copies of a single strand mRNA located in the viral core.  
These two mRNA copies serve as the HIV-1 viral genome. The full-length HIV-1 genome is 
approximately 9.7kb long. This genome contains nine genes coding for fifteen viral proteins. 
Figure 2-2 below shows the HIV-1 genomic structure. The proteins encoded by HIV-1 mRNA 
are classified into three groups: a) major structural proteins, b) regulatory proteins, and c) 
accessory proteins. The major structural proteins include a group-specific antigen (Gag), 
polymerase (Pol) and envelope (Env) proteins. Gag, Pol and Env are produced as 
polyproteins that are subsequently cleaved by protease to form individual proteins. Gag later 
becomes mature proteins, such as matrix (MA), capsid (CA) and nucleocapsid (NC). Gag 
expression alone is responsible for immature virus-like particles that bud from plasma 
membranes. Therefore, Gag proteins must interact with other components to form mature 
viruses. Together with pol, gag-pol encodes viral enzymes including reverse transcriptase 
(RT), integrase (IN), protease (PR) and DNA polymerase. The env gene encodes surface 
glycoprotein (SU) and transmembrane (TM) proteins of the virion. During early infection, 
these proteins form a complex that interacts specifically with chemokine receptor proteins 
on the targeted cell surface, such as CD4, CCR5 and CXCR439.  
 
Figure 2-2. HIV-1 genomic structure 
The HIV-1 genome composes of 3 major genes; gag, pol and env. Gag gene encodes matrix (MA), 
capsid (CA), nucleocapsid (NC) and p6 protein. Gag-pol genes encode protease (PR), reverse 
transcriptase (RT) and integrase (IN). Env gene encodes surface glycoprotein (SU) and 
transmembrane glycoprotein (TM). By splicing mechanisms, the HIV-1 genome also encodes viral 
accessory proteins such as Vif, Vpr, Vpu and Nef, as well as regulatory proteins such as Tat and 
Rev. 
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As a result of multiple mRNA splicing, HIV-1 genome produces accessory proteins such as 
viral protein unique (Vpu), viral protein R (Vpr), viral infectivity factor (Vif) and negative 
regulatory factor (Nef), also regulatory proteins include trans-activator of transcription (Tat) 
and regulator of expression of virion proteins (Rev)40. Tat protein is essential in regulating 
HIV-1 transcription and has diverse functions in HIV-1 pathogenesis, and therefore will be 
discussed further in this review. 
2.3 Trans-activator of transcription (Tat)  
Tat protein is expressed early after HIV-1 provirus is formed in the host cells. This protein is 
an important regulatory protein of HIV-1 as it has so many roles in HIV-1 replication cycle 
and pathogenesis. Tat open reading frame (ORF) has two exons separated by an intron. As 
a result of double mRNA splicing, the intron is removed, forming a Tat transcript that 
encodes 86-101 amino acids. The first exon of Tat consists of proline rich region, cysteine 
rich region, core region, arginine rich region (basic domain) and glutamine rich region41.  
Tat N-terminus domain plays a role in T cell immunosuppression by binding to dipeptidyl 
peptidase IV, a T cell activation marker (CD26) important in regulation of lymphocyte growth. 
This way, this proline rich region inhibits DNA synthesis in T cell lymphocytes42.   Tat 
cysteine-rich and core regions induce migration and invasion of monocytes during HIV-1 
expansion43, while the glutamine rich region involved in T-cell apoptosis44. Tat basic domain, 
at position 49-57, plays an important role in enhancing HIV-1 transcription by RNA 
polymerase II. During early transcription, the basic domain of Tat binds to HIV-1 trans-
activation response (TAR) RNA (Fig. 2-3). TAR RNA is a hairpin structured RNA located at 
the 5’ HIV-1 LTR end serves as cis acting site for transactivation45. 
The bulge structure of TAR RNA plays a role as a Tat binding site. However, Tat binding to 
TAR RNA only is not enough to stimulate transactivation46. The stem-loop structure of TAR 
RNA supports transactivation by Tat as it binds to cyclin T147. Tat also binds to cyclin T1 
surface and interacts with CDK9. Both cyclin T1 and CDK9 are part of P-TEFb, a host protein 
that is responsible for controlling gene expression in eukaryote cells. A study on Tat-P-TEFb 
crystal structure shows Tat binds to both Cyclin T1 and CDK948. CDK9 has a role in 
phosphorylating the C terminal domain of RNA polymerase II. It was observed that Tat 
protein alone has a flexible structure, but when it interacts with P-TEFb complex, Tat 
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acquires the stable conformation required for its transcriptional function. Tat changes its 
conformation by directly binding to both Cyclin T1 and CDK9. Tat cysteine-rich and core 
regions interact with two Zn ions to form a compact structure. One of these Zn ions forms a 
bridge with Cyclin T1. Mutational studies reported that His33 and all cysteine residues of 
Tat are important for this interaction, except Cys31, which often is replaced by serine in 
subtype C Tat, as this mutation does not change the protein function. The first 49 amino 
acids of Tat, ~37% of its folded surface, is complementary to the kinase. Consequently, Tat 
has a strong binding affinity with P-TEFb complex.  This interaction changes CDK9 
conformation and activates P-TEFb by altering its substrate binding surface48. Shortly after 
transcription initiation, negative elongation factor (NELF) interacts with DRB sensitivity 
inducing factor (DSIF), causing RNA polymerase II promoter-proximal pausing. Activated P-
TEFb reverses this RNA polymerase II inhibition by phosphorylating NELF and DRB 
sensitivity inducing factor (DSIF)48. It also phosphorylates Ser2 and Ser5 in the carboxy 
terminal domain of RNA polymerase II, enhancing HIV-1 transcription processivity. Without 
Tat activation of P-TEFb, mRNA synthesis by RNA polymerase II is inefficient due to the 
promoter-proximal pausing, and results in short transcripts41,49. 
 
Figure 2-3. Diagram of HIV-1 Tat-mediated transactivation 
Tat binds TAR RNA from the HIV-1 LTR then recruits pTEFb that is compose of Cyclin T1 and CDK9. 
This complex then hyperphosphorylates the carboxy terminal of RNA polymerase II, and in this way 
Tat enhances transcription efficiency. 
Tat also has several functions in HIV-1 pathogenesis. Tat induces apoptosis in CD4+ T cells, 
and this results in depletion of CD4+ T cell lymphocyte numbers in HIV patients along with 
other mechanisms.  Tat is expressed in the cytoplasm and can cross the membrane into the 
nucleus. Tat can also be released from infected cells and induces apoptosis in uninfected 
bystander cells. This mechanism is reported as the main cause of CD4+ T cell lymphocyte 
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depletion in HIV patients50. However, Tat has been reported elsewhere to induce cell 
proliferation. A small concentration of Tat released from infected cells was able to induce 
proliferation of human epithelial cells51. This may explain incidents of AIDS-related cancer 
in HIV patients. Extracellular Tat was reported to induce Kaposi sarcoma51. Extracellular Tat 
can enter bystander cells and stimulates inflammation cytokines such as TNF-β, TGF-β and 
IL-6. It is also reported that Tat can inhibit immune response mediated by MHCII 
presentation and IL-241. 
Tat is unique in having free cysteine residues in region II that support structure flexibility. 
The flexible structure of Tat protein is necessary for its diverse functions, from binding to 
RNA to crossing host cell membranes48. Tat can cross the blood brain barrier and causes 
HIV-associated neurocognitive disorder (HAND)52. Because of its abundant functional roles 
in HIV-1 replication and pathogenesis, Tat is a promising target for antiviral therapy. 
2.4 HIV-1 life cycle 
The HIV-1 life cycle starts from virus fusion, reverse transcription, integration, transcription 
and translation, followed by virus maturation and budding in the late phase of infection 
(Figure 2-4). 
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Figure 2-4. HIV-1 life cycle  
The HIV-1 life cycle starts from; (1) virus fusion to the target cell, (2) uncoating and release the HIV-
1 genetic material into the cell, (3) reverse transcription, (4) integration to the host chromosome, (5) 
transcription, (6) mRNA export from the nucleus to the cytoplasm, (7) translation, (8) assembly and 
(9) a new virus budding and maturation. 
The HIV-1 life cycle can be divided into an early and a late phase of viral replication. The 
early phase includes the steps from viral fusion until integration, while the late phase starts 
with transcription and is finished by release of a mature new virion. Details of virus life cycle 
stages are described below. 
2.4.1  Virus fusion and entry  
HIV infects lymphocytes, monocytes, macrophages and dendritic cells. The HIV life cycle 
begins when the virus penetrates the host cells. The infection starts when the external part 
of the viral HIV envelope protein, gp120, attaches to a CD4 molecule on the target cell 
surface. This attachment changes the conformation of gp120 to enable binding to CCR5 or 
CXCR4 chemokine receptors in the host cell. This step is followed by a transmembrane 
protein (gp41) activity that allows cell fusion with the viral envelope35. Conformation change 
happens so that gp41 forms a coiled structure that exposes the hydrophobic region of gp41 
and enables the virus to fuse with the lymphocyte cell membrane53. After that, the viral 
capsid releases the viral core, containing RNAs and proteins, into the host cell cytoplasm35.  
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2.4.2 Reverse transcription 
The viral RNA is then reverse transcribed into its complementary DNA (cDNA) by reverse 
transcriptase activity. This step results in viral genome that is transported into the nucleus. 
This transport is aided by nuclear signal transduction from the p17 matrix protein53, Viral 
protein R (Vpr), Viral protein U (Vpu) and transportin-335. Subsequently, the viral RNA 
template is degraded by ribonuclease activity.  
2.4.3 Integration 
The next step of HIV-1 life cycle is DNA integration, which serves to stabilize the viral cDNA 
in the host chromosome54. A cofactor named human lens epithelium-derived growth factor 
75 (LEDGF75) interacts with integrase and enhances strand transfer activity during the viral 
genome integration. Once the viral genome is inserted into the host chromatin, a provirus is 
formed55.  
2.4.4 Transcription, nuclear transport and translation 
RNA polymerase II in the cytoplasm initiates transcription of the integrated DNA into mRNA. 
Due to the splicing process, transcription results in short mRNA transcripts during the early 
stage of infection. Small and doubled spliced mRNAs encode Tat, Rev and Nef. Singly 
spliced mRNAs encode Env, Vif, Vpr and Vpu, while unspliced full length mRNAs encode 
Gag and Pol. Next, translation occurs in the cytoplasm forming proteins that are transported 
further into the nucleus through the nuclear import mechanism11. The first protein that is 
produced from this process is Tat. As described in section 1.4, Tat is important for HIV-1 
transcription as it enhances the transcription processivity.  
Rev prevents full length RNA splicing and increases the nucleocytoplasmic transport of the 
viral mRNAs3,56. Rev is transported from the cytoplasm to the nucleus through the interaction 
of its arginine rich nuclear localization signal (NLS) with transportin or importin β. Mediated 
by nucleophosmin, Rev is then transported into the nucleolus. In the nucleolus, Rev forms 
a complex with unspliced or singly spliced HIV-1 RNA containing Rev response element 
(RRE). RRE is a ~350 nucleotide recognition sequence located at the envelope region of 
unspliced or singly spliced HIV-1 RNA. Rev multimerization on the RRE masks Rev’s NLS 
and exposes its nuclear export signal (NES). Rev then interacts with nuclear export factors 
and chromosome region maintenance 1 (CRM1), which mediates transport of unspliced and 
singly spliced RNAs into the cytoplasm57.  
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2.4.5 Budding and maturation 
The full length mRNAs are translated into Gag and Gag-Pol, while singly spliced mRNAs go 
on to make Env, Vif, Vpr and Vpu53,54. Gag assists the virus assembly by binding to the 
plasma membrane, mediating protein-protein interaction to create a spherical particle and 
interacting with RNA packaging sequence to package the HIV-1 genomic RNA. An immature 
virus is then ready to bud through the plasma membrane. During budding, the amino-
terminal Gag domain binds to the plasma membrane and recruits envelope glycoprotein to 
encapsulate the virion. Protease is activated as the immature virion buds. Gag is then 
undergone proteolysis into viral structural proteins, such as matrix, capsid and 
nucleocapsid. Gag-Pol , a protein precursor generated from ribosomal frame shift,  is 
cleaved by protease and forms reverse transcriptase, integrase and protease35. At the end 
of this stage, a mature virion is formed and ready to be released from the cell and infect 
another target cell58.  
2.5 HIV-1 pathogenesis and disease progression 
HIV-1 disease progression includes acute infection stage, clinical latency infection and 
AIDS. Figure 2-5 explains how untreated HIV-1 infection progressing by time indicated by 
depletion of CD4+ lymphocytes in relation with viral load levels59,60. These three stages are 
discussed below. 
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Figure 2-5. Time course of disease progression in untreated HIV-1 infection  
Viral load levels are shown in correlation with depletion of CD4+ lymphocyte count at time indicated. 
2.5.1 Acute infection stage 
Acute infection stage occurs during HIV-1 exposure and completion of initial immune 
responses. This stage, also called seroconversion, may last for few weeks to 3 months. 
Seroconversion is the period between initial infection and development of detectable levels 
of antibodies. During the first 2 to 6 weeks after HIV-1 infection, HIV-1 infected patients 
produce virus in large amounts as well as mounting a robust immune response. High rate 
of viral replication and the immune response generation during seroconversion cause 
severe flu-like symptoms, the acute retroviral syndrome, which may include fever, swollen 
glands, rash, headache, myalgia, arthralgia, lethargy/malaise, pharyngitis and fatigue61. 
Lymphadenopathy, anorexia, nausea, mucus membrane ulcers, night sweats, diarrhea and 
weight loss have also been reported61,62. A recent case report from 10 acute HIV infected 
patients indicated hemophagocytic lymphohistiocytosis, a systemic inflammation 
condition63. 
HIV-1 replicates in CD4+ T cell lymphocytes and causes cell death. Therefore, CD4+ T cell 
count falls dramatically and the viral load increases during the acute infection stage64. A 
cohort study of 284 HIV infected individuals in Thailand showed that administration of cART 
in this stage suppressed the viral load up to ~2.5-fold by day 12, ~135-fold by day 30 and 
~1148-fold by day 12065. Taking antiretroviral during this stage helps to decrease the viral 
18 
 
load as well as increase the CD4+ T cell count and also reduce the duration of acute 
retroviral syndrome66.  
2.5.2 Clinical latency stage 
After the acute infection stage, the disease moves to clinical latency stage. This phase is 
also called chronic HIV infection or asymptomatic HIV infection. During this period CD4+ T 
cell count decreases steadily. This phase is asymptomatic and may last for about eight 
years. The latently infected cells create a barrier for HIV-1 eradication 67.  
HIV latency occurs when provirus is formed in CD4+ T cells but translation machinery is 
shutdown68. The HIV latency reservoir is generated when infected CD4+ T cell lymphocytes 
survive the HIV cytopathic effect and the increased immune response. This leads to the 
development of cell memory in resting CD4+ T cells carrying integrated provirus, but cannot 
facilitate viral gene expression69. In the resting T cells,  Cyclin T1 is degraded and Tat 
production declines68. The lack of these host and viral factors cause limited activity of the 
HIV-1 long terminal repeat during transcription70, and therefore very low levels of HIV-1 
plasma viremia are present in this latency stage. However, these resting CD4+ T cells may 
become reactive when the cART treatment is discontinued, or fails due to drug resistance, 
and lead to a rebound of viremia69,71.  Furthermore, induction of Tat production can 
reactivate HIV transcription, replication and spread. Latency reactivation can also occur as 
a result of cell stimulation by cytokines or T cell receptor activation68.  
2.5.3 AIDS 
In the late stage of infection, the capability of the immune system decreases significantly 
and the patient becomes vulnerable to cancer and opportunistic infections. The CD4+ T cell 
count falls below 200 cells/mm3 and clinical manifestations including pulmonary, 
gastrointestinal, neurologic and cutaneous diseases follow. Without appropriate treatment, 
the life expectancy for patients in this stage is about three years and may decrease to about 
one year with opportunistic infections72-74.  
2.6 HIV distribution  
HIV is part of Retroviridae family and a member of Lentivirus genus. Based on the sequence 
differences of the viral genomes, HIV is classified into HIV-1 and HIV-2. Based on 
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evolutionary comparisons, both HIV-1 and HIV-2 arose from multiple cross-species 
transmissions of Simian Immunodeficiency Virus (SIV). The origin for HIV-1 was SIV in the 
chimpanzee, while for HIV-2, it was the sooty mangabey SIV75. HIV-1 is most prevalent 
worldwide and will therefore be the focus of this section. 
HIV-1 genetic diversity remains a major obstacle for the virus eradication. Extensive genetic 
diversity of HIV-1 has been characterized. The viral genetic diversity emerged due to the 
rapid rate of viral mutation, replication and recombination76. Among the multiple factors that 
contribute to genetic variation, errors during virus replication are the most likely causes of 
the mutations77. HIV-1 replication involves three different polymerases. The enzyme best 
known to trigger mutations is reverse transcriptase, a viral enzyme that converts HIV-1 RNA 
to cDNA. Reverse transcriptase has low fidelity when transcribing RNA into DNA because 
it lacks proofreading activity76,78,79. DNA polymerase can also contribute to mutations during 
replication of the integrated provirus. However, this is thought to be a less important source 
of error because cellular DNA replication is known to be less error-prone76,80. Mutations can 
also occur during transcription by RNA polymerase II79, but this polymerase possesses 
transcriptional proofreading81-83, and therefore mutations caused by this enzyme are less 
frequent relative to those caused by reverse transcriptase. Genetic variation in HIV-1 can 
also be caused by environmental and host factors84. In addition, recombination can also 
cause HIV-1 variations, known as Circulating Recombinant Forms (CRF). The HIV-1 virion 
contains two strands of viral genomic RNA. Recombination can occur when a person is 
coinfected with more than one virus from related or different strains of HIV-1. CRFs are 
formed when single cell harbors two or more different proviruses, and one RNA transcript 
from each provirus is encapsidated form a new virion. When this new virion infects another 
cell, reverse transcription happens between the two RNA synthesizing a recombinant form 
of cDNA12. Currently, over 90 CRFs have been assigned and these CFRs account for ~20% 
HIV-1 infection worldwide85. 
Based on envelope nucleotide sequence differences, HIV-1 has four distinct lineages: 
groups M, N, O and P75. Worldwide, group M is the most prevalent type of HIV-1, and is 
classified into nine major subtypes or clades (A-D, F-H, J-K) and a small number of 
recombinant forms of those subtypes36,53,75. The geographical distribution of HIV-1 variants 
is summarized in Table 2-1 below. 
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Table 2-1. Distribution of HIV variants75,84 
 
Group Subtype /Clade Distribution 
M A East and central Africa, Central Asia, Europe 
 
B America, Western Europe, East Asia, Oceania 
C India, South and East Africa, Brazil 
D East Africa 
F Central Africa, Romania, Latin America 
G Eastern and Western Africa, Taiwan, Russia 
H Central Africa, Belgium 
J Central America 
K Cameroon 
A/E South East Asia, China, Central Africa 
A/D Central Africa 
A/G Eastern and Western Africa, Central Europe 
N  West Africa, Cameroon 
O  Cameroon, Gabon, Equatorial Guinea 
P  Cameroon 
  
HIV-1 is divided into two classes based on the use of chemokine receptors: R5 infecting 
macrophages and T lymphocytes by binding to CCR5 co-receptor, and; X4, infecting T 
lymphocytes by binding to CXCR4 co-receptor86. The subtype or clade variation of HIV-1 
correlates with the use of different co-receptors and different disease progressions. Subtype 
A and C viruses, for example, are associated with exclusive use of CCR5 co-receptor even 
in the late stage of disease progression, whereas subtype D viruses tend to use both CCR5 
and CXCR4 co-receptors (R5X4). CXCR4 virus is correlated with faster disease 
progression87. It has been reported that subtype C causes the fastest disease progression, 
while subtype A and G have the slowest disease progression88. Subsequent studies found 
that subtype D and its recombinant forms, such as subtype AD, caused faster disease 
progression compared to subtype A87,89,90.  
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The HIV-1 diversity also impacts on drug susceptibility. For example, non-B subtypes 
develop drug resistance more rapidly than B subtype viruses84. This is a challenge for HIV-
1 eradication and hence a broad spectrum of HIV therapeutic strategy is required to 
overcome this problem. 
2.7 A Resurgence in Gene Therapy as an Approach to Curing HIV/AIDS 
HIV therapy research has included novel HIV therapeutic interventions such as gene 
therapy. Gene therapy is the use of genes to prevent or treat diseases by replacing mutated 
genes that cause diseases, knocking out target genes or introducing a new gene to fight 
diseases. Gene therapy for HIV-1 is mainly aimed at making cells resistant to HIV-1. 
Conventional therapy using cART is a long-life treatment that requires multiple dosages of 
medication. Compared to that conventional therapy, gene therapy may provide an 
advantage as it offers an ongoing manner therapy with a single shot treatment. Several 
gene therapy approaches to combatting HIV-1 that have been through preclinical and 
clinical trials are discussed below. 
2.7.1 Anti-Tat single chain intrabody 
An intrabody is an intracellular antibody that is designed to specifically bind to a protein 
target in cells. Anti-Tat intrabody is an intracellular antibody that binds Tat protein. The Anti-
Tat intrabody protein binds to the proline rich region in Tat, located across amino acids +1 
to +19 from the N terminal of Tat23. This region is an important epitope of Tat for 
transactivation function.  
An intrabody variant called anti-Tat sFvs1 inhibits Tat-mediated transactivation as well as 
syncytia formation and HIV-1 replication. This single chain antibody is abundantly expressed 
in the cytoplasm and nuclear compartment of transduced primary CD4+ T cells without any 
detectable cytotoxicity91. This variant has been developed into a humanized antibody named 
sFvhuTat2 that has undergone a pre-clinical study in mice and a clinical trial on HIV 
patients23. Using an MLV based vector, transduction efficiency of CD4+ T cells by sFvhuTat2 
was 28%. These transduced cells were able to expand up to 30 days. Viral load was 
suppressed up to ~80pg/ml CAp2492. These studies indicate that, delivered by a lentiviral 
system, sFvhuTat2 may prevent HIV-associated neurotoxicity in mouse neuron cells and 
suppress HIV replication in vitro93. Furthermore, the action of sFvhuTat2 against Simian HIV 
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(SHIV) in rhesus macaques has been studied using a retroviral delivery system, and this 
intrabody has been found to cause a decrease in viremia by 3-fold, as well as prolonged 
CD4+ T cell survival post infection94.   
Extensive research has been performed in order to optimize the use of this intrabody for 
HIV gene therapy. However, transduction efficiency of huTat2 delivered by a lentiviral vector 
in primary cells was low. Furthermore, the in vivo model developed to examine huTat2 only 
represents acute but not chronic HIV-1 infection93. Another limitation of the use of 
intrabodies for HIV treatment is that a single chain antibody usually has low affinity to the 
target protein partly because of incorrect folding in the reducing environment of the 
cytoplasm95. More extensive clinical trials are required to improve this gene therapy efficacy. 
2.7.2 Tat/vpr anti_HIV-1 specific ribozyme  
Phase I and II clinical trials were conducted to examine safety and efficacy of gene therapy 
using a tat/vpr anti HIV-1 specific ribozyme (OZ1)96,97. Ribozymes are small RNA composite 
molecules that catalyse cleavage of phosphodiester link of complementary RNA 
fragments98. OZ1 contains a ribozyme that targets the overlapping vpr and tat RNA 
sequences. Using an MLV based vector, OZ1 was delivered to CD34+ hematopoietic 
progenitor cells and transplanted to 38 HIV-1 infected patients97.  The result showed no 
serious adverse effect up to 5 years post transplantation. Slightly decreased viral load (up 
to 10.000 copies/ml) was observed in OZ1 treated patients at week 40-48. However, low 
engraftment levels of OZ1 transduced CD34+ cells (0.01%-0.38%) were detected in the 
peripheral blood 97. Further studies are required to improve the efficacy of OZ1, for example 
by increasing the number of transduced CD34+ cells to obtain better engraftment levels. 
2.7.3 RevM10 
Clinical studies using a Rev mutant protein as a therapeutic approach found that Rev M10 
can inhibit HIV replication. RevM10 is a Rev mutant protein that acts as a transdominant 
negative protein against wild type Rev activity during HIV replication. RevM10 was created 
by substitution of two amino acids in the NES region of wild type Rev that interact with 
CRM1. Rev is an HIV regulatory protein that plays a role in nuclear localization, RNA binding 
and nuclear export99. During the HIV replication process, Rev binds to RRE, a stem loop 
RNA element located in the envelope coding region of the viral genome. The Rev-RRE 
complex mediates the transport of unspliced and singly spliced viral mRNAs from the 
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nucleus to the cytoplasm100. RevM10 multimerizes by forming a non-functional heteromeric 
complex with Rev and thus prevents wild type Rev from interacting with CRM1101. 
Introduction of RevM10 to human T cells inhibits Rev activity, preventing export of Rev-
dependent viral mRNAs from the nucleus by disrupting CRM1 binding sites and 
consequently inhibiting HIV-1 replication102.  
Subsequent clinical trials of RevM10 in HIV-1 patients using non-viral and retroviral vectors 
showed the survival rate of CD4+ T cells expressing RevM10 was higher than that of 
untreated cells102,103. This suggests RevM10 protects cells from HIV-1. However, a 
subsequent study found this therapy cannot eliminate viral loads in blood plasma because 
HIV-1 may develop mutations in a RRE region that alter the structure of RRE and thus 
causes resistance to RevM10104. Another clinical trial using CD34+ cells transduced by 
RevM10 transplanted in HIV-1 patients showed the transplanted cells survived for four 
months but gradually diminished over two years105. Further study should focus on 
anticipating resistance to RevM10 as well as improving cell survival. 
2.7.4  siRNA 
Another gene therapy approach is downregulation of CCR5 expression using small 
interfering RNAs (siRNA). siRNA targeted gene silencing is achieved through the RNA 
interference (RNAi) pathway106. siRNA can be introduced into mammalian cells to induce 
degradation of specific intracellular RNA40. One form of siRNA that stably inhibits HIV-1 is 
short hairpin RNA (shRNA)107. A highly efficient shRNA called shRNA1005 has been found 
to downregulate CCR5 expression in systemic lymphoid organs in a mouse model without 
showing toxicity107. The gene knock-down was stably maintained long term as indicated by 
sustained downregulation of CCR5 expression in CD34+ transplanted animals. Ex vivo, the 
downregulation of CCR5 by shRNA1005 was shown to be able to inhibit CCR5 HIV-1 
infection107. Furthermore, a clinical study of downregulation of CCR5 by siRNA was carried 
out in patients undergoing transplantation for AIDS-related lymphomas. The expression of 
siRNA and ribozyme in peripheral blood samples was maintained up to 24 months after 
stem cell infusion and the viral loads were undetectable for patients maintained on cART 
treatment108.  
Recent studies utilized shRNA named shPromA to inhibit HIV-1 transcription was conducted 
by Kazuo and colleagues. It was reported that shPromA induced transcriptional gene 
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silencing (TGS) of HIV-1 by targeting conserved region in the tandem repeat NFκB 
sequence in the U3 region of HIV-1 5’LTR in MOLT-4 and Hela cells109.  This shPromA is 
sequence specific to HIV-1 NFκB and therefore the possibility of off-target effects is 
minimum110. An in vivo study using a (NOD)/SCID/Janus kinase 3 (NOJ) knockout 
humanized mouse model showed that shPromA can prevent CD4+ T cell depletion and 
lower the plasma viral load111.  
NFκB binding region is conserved in most HIV-1 subtypes, except for subtype C that can 
have three possible NFκB binding regions. Therefore, a double-stranded RNA (ds RNA) 
termed S4-siRNA was created subsequently to target subtype C HIV-1 promoter109,112. S4-
siRNA induces TGS by histone methylation mechanism that forms heterochromatin of the 
HIV-1 LTR. This ds RNA showed long term suppression of HIV-1 subtype C in TZM-bl and 
peripheral blood mononuclear cells (PBMCs)112. 
These siRNA approaches can be promising to block HIV-1 transcription and enforce long 
term TGS suppression. However, HIV-1 may develop mutations by nucleotide substitution 
or deletion in or near the siRNA target sequence. Such mutations may cause mismatches 
with the siRNA or alter the RNA folding and prevent binding to siRNA so that HIV-1 can 
escape from siRNA mediated gene silencing113.  
2.7.5 Zinc Finger Nuclease 
Zinc Finger Nuclease (ZFN) technology is useful for genome engineering of various 
organisms including human cells. ZFN induces a double strand break (DSB) in a specific 
target sequence that can be followed by desired gene modifications. ZFN has a region 
containing a Cys2-His2 zinc finger that can recognize three base pairs of DNA as a binding 
site, fused with a nuclease enzyme that can cut DNA at that binding site. Consequently, 
ZFN can be used to mutate a targeted gene in order to knockout the gene114,115.  
It has been reported that ZFN therapies can produce HIV-1-resistant CD4+ T cells. A clinical 
study on 12 patients using ZFNs to knock out the CCR5 gene in CD4+ T cells showed a 
significant increase in the CD4+ T cell count of all the patients one week after modified CD4+ 
T cell infusion116. The modified CD4+ T cell half-life was approximately 48 weeks. Modified 
CD4+ T cells were found to survive longer than unmodified CD4+ T cells and the viral load 
in the blood decreased after the treatment. This research also found that T cells were mostly 
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found in mucosal tissues, as indicated in rectal biopsy specimens. These findings suggest 
that the modified cells were engrafted and that the CCR5 gene deletion provides protection 
to CD4+ T cells against HIV infection. However, adverse events following this treatment were 
also found. These included fever, chills, joint and back pain116. 
2.7.6 Nullbasic 
A novel transdominant negative HIV-1 Tat protein termed Nullbasic has been shown to have 
a strong antiviral activity against HIV-1 infection in vitro. Nullbasic is considered to be a Tat 
transdominant negative protein because it can block the activity of wild type Tat. Nullbasic 
has a unique ability to potently inhibit multiple steps of HIV-1 replication. Nullbasic is a 
mutant of Tat, a small viral regulatory protein critical for enhancing the HIV-1 transcription 
efficiency from the LTR transcriptional promoter13. Wild type Tat has an arginine-rich basic 
domain with an important role in mediating TAR RNA binding. In Nullbasic, this domain 
contains glycine and alanine residue substitutions (Figure 2-6).  
 
Figure 2-6. Schematic of Tat and Nullbasic domains 
Tat protein is encoded by two exons. The first exon encodes five domains, as shown, including a 
basic domain rich in arginine. In Nullbasic, the basic domain is mutated to be glycine rich with an 
alanine residue. 
Nullbasic has potential as a therapy to prevent the spread of HIV infection, showing strong 
inhibition of HIV-1 replication in vitro in primary CD4+ T lymphocytes15. Nullbasic interferes 
with HIV-1 replication by targeting three steps in the HIV-1 life cycle, including Tat-mediated 
transactivation, Rev-mediated transport of HIV-1 mRNA16, and reverse transcription15. 
Nullbasic obstructs Tat interaction with P-TEFb during early transcription because Nullbasic 
can compete with Tat for binding to P-TEFb, and therefore it is considered as a 
transdominant negative inhibitor of wild type Tat. Unlike Tat, Nullbasic does not activate 
HIV-1 transcription15,17. Furthermore, Nullbasic has been shown to inhibit HIV-1 reverse 
transcription, resulting in the suppression of virion infectivity. Nullbasic binds directly to RT 
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subunit p51 as well as p66 and disrupts the reverse transcription complex, thereby causing 
premature viral uncoating15. Nullbasic has also been shown to interfere with Rev 
nucleocytoplasmic transport activity and thereby disrupt the Rev nucleolar organisation and 
functions. Recently, it was shown that Nullbasic specifically targeted the cellular RNA 
helicase DDX1, which is a Rev binding protein that regulates its function in mRNA transport. 
DDX1 directly interacts with the multimerization domain of HIV-1 Rev protein to promote 
Rev oligomerization on the RRE16. As a consequence, Nullbasic downregulates the 
expression of unspliced and singly-spliced HIV-1 mRNAs and therefore inhibits virus 
replication15. 
However, the antiviral activity of Nullbasic against HIV-1 has only been tested on a 
laboratory clade B virus strain12. Genome variations between different clades may result in 
amino acid substitutions in viral proteins that can influence susceptibility of the virus to 
antivirals84. Hence, more research into Nullbasic antiviral activity against different clades of 
HIV-1 is necessary. 
2.8 Humanized Mouse Models for HIV Research  
In order to generate preclinical data about promising HIV gene therapy approaches, 
appropriate animal models are required. Nonhuman primates such as chimpanzees are 
genetically and physiologically similar to humans. In term of disease susceptibility, a 
chimpanzee is the only non-human animal that is naturally susceptible to infection with HIV 
and therefore is considered as the gold standard of animal model for HIV. However, the use 
of this primate for biomedical research is prohibited in many countries due to ethical issues. 
This leads to generation of small animal models to represent the human biological system 
and disease susceptibility, such as humanized mouse models. The humanized mouse 
model is less laborious and less costly than the primate model.  
Humanized mouse models are immunodeficient mice engrafted with functional or modified 
human cells or tissues or human transgenes117. Based on the aim of experiments, different 
kinds of humanized mouse models are utilized. For example, mice transplanted with PBMC 
obtained from human blood allow investigation of human CD4+ T cell depletion, viral load 
levels and the effect of therapeutic interventions against HIV infection. This model provides 
rapid and reproducible data in HIV therapy research118. The mice can also be transplanted 
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with hematopoietic stem cells (HSC) isolated from human cord blood or fetal liver to study 
a completely naïve immune system during HIV infection. This model sustains human 
hematopoietic cell engraftment over a longer time frame118. 
The discovery of humanized mouse models in HIV-1 research was summarized in Table 2-
2. Severe combined immunodeficiency (SCID) mutation in mice has led to the development 
of a humanized mouse model (hu-PBL-SCID) through grafting of human peripheral blood 
lymphocytes (PBL)119. Because of the SCID mutation, these mice lack functional T cells and 
B cells and hence are unable to mount immune responses to reject xenogeneic 
transplants119. The potential of this model to support a pathogen that replicates in human 
cells such as HIV was investigated, but studies indicate this model only shows a low level 
of human cell engraftment (0.5-5%) and is unable to mimic human adaptive immune 
responses against HIV-1 infection120. In addition, at 10-14 weeks old, SCID mice become 
leaky and generate unwanted functional T and B cells as well as natural killer (NK) 
activity120. In order to eliminate NK activity, a non-obese diabetic SCID (NOD-SCID) mouse 
model was developed. Unfortunately, the NOD mutation often causes thymic lymphomas 
that shorten the life span of the mice121. 
As an alternative, a new generation of humanized mouse models was developed through 
mutation of recombination-activating gene (RAG). RAG1 and RAG2 proteins play an 
important role in forming an enzyme complex that joins T and B cell receptor genes. The 
RAG deficient mice were not leaky in T and B cell production and less radiosensitive 
compared to the SCID mice. Yet, RAG1 and RAG2 mice generate unwanted NK cells so 
mutations of common gamma chain receptor (γc) to prevent NK cell maturation were also 
required. The gamma chain is an important subunit protein of interleukin receptors, including 
IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. The lack of IL-2 and IL-7 signaling prevents T and B 
cell development as well as NK cell maturation122. This resulted in BALB/c-Rag1-/-γc-/- and 
BALB/c-Rag2-/-γc-/- that are susceptible to PBL or hematopoietic stem cell (HSC) 
transplantation and HIV infection. 
The BALB/c-Rag2-/-γc-/- mouse is susceptible to transplantation of human PBL or HSC. The 
level of human cell engraftment ranged from 5-85%. Humanized mice grafted with HSC are 
receptive to infection of R5 and X4 tropic HIV-1, and exhibit prolonged viremia (up to 30 
weeks) and CD4+ T cell depletion as in humans. Also, BALB/c-Rag2-/-γc-/- mice develop a 
28 
 
functional human immune system123,124. Thus, this model is useful for investigating gene 
therapy against HIV-1. 
Table 2-2. Humanized mouse models for HIV infection studies 
Mouse Model Advantages Limitations 
SCID Lacking B cells and T cells  Low levels of engraftment 
Unable to mimic human 
adaptive immune responses 
against HIV-1 
After 10-14 weeks can 
generate B cells, T cells and 
NK 
Radiosensitive 
NOD-SCID Lacking NK  Develop thymic lymphoma 
Radiosensitive 
RAG1 and RAG2 Lacking B cells and T cells 
Non-radiosensitive 
Generate NK 
 
Gene therapy may be the answer for a functional cure of patients with HIV-1/AIDS. Have 
been extensively studied, Nullbasic, with its combined antiviral mechanisms, can be a 
promising gene therapy agent against HIV-1.  In the next chapter, Nullbasic antiviral activity 
against diverse HIV-1 strains from different subtypes will be elucidated.  
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CHAPTER 3  
Nullbasic Inhibits Replication of Different HIV-1 Strains from Diverse 
Subtypes in Human Cells  
 
3.1 Introduction 
The HIV-1 pandemic remains a huge social and economic burden. By 2014, 36.9 million 
people were living with HIV and 1.2 million AIDS related death cases were reported4. One 
of the major obstacles in treating this disease is the high genetic diversity of HIV-1 that leads 
to different rates of disease progression and drug resistance to antiviral drugs11,125. We have 
investigated an anti-HIV-1 agent that targets three different steps of virus replication by 
targeting viral and cellular proteins, and therefore may have efficacy against HIV-1 with 
diverse genetic backgrounds. 
The agent is a Tat mutant protein derived from subtype B HIV-1BH10 that strongly inhibits 
HIV-1 replication in human cells15, and is referred to as Nullbasic. Wild type Tat is an 
essential HIV-1 protein required for transactivation of the HIV-1 LTR promoter, resulting in 
high levels of viral mRNA transcription by RNA polymerase II126. It also plays a role in HIV-
1 reverse transcription127,128.  HIV-1 virions lacking tat gene were unable to initiate reverse 
transcription128. Furthermore, recombinant Tat proteins were able to enhance reverse 
transcription in a RNA independent manner, through Tat-RT interaction127. Tat is also 
involved in other cellular processes, such as immune suppression and induction of 
inflammatory cytokines41,129,130.  Tat causes immune suppression by binding to CD26, a T 
cell activation marker that plays a role in lymphocyte growth, as well as inhibiting dipeptidyl 
peptidase IV, an exopeptidase important for lymphocyte proliferation and activation42. 
Induction of inflammation by Tat occurs via by stimulating production of IL-6 and IL-8 
cytokine production in dendritic cells and monocytes via the NF-kB activation pathway131. 
Tat can also induce cell apoptosis by hyperactivation of CD8+ T cells122,132. 
Nullbasic, which has been described previously2,15,127, has a substitution mutation spanning 
the entire basic domain; amino acids 49 to 57, RKKRRQRRR, are replaced with 
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GGGGGAGGG. Studies show that Nullbasic is expressed in cells and located in the nucleus 
and cytoplasm16 , and inhibits HIV-1 replication by: 1) inhibiting HIV-1 transcription by RNA 
polymerase II through interaction with p-TEFb and causing epigenetic silencing of the HIV-
1 LTR 2,14,15; 2) inhibiting Rev-dependent viral mRNA transport from the nucleus by binding 
to DDX13,16, and; 3) inhibiting reverse transcription by directly interacting with reverse 
transcriptase, leading to accelerated uncoating kinetics post-infection and defective viral 
DNA synthesis18. 
HIV-1 sequence diversity is categorized by HIV-1 subtypes that are defined by comparisons 
of env genes. These subtype variations can also be observed as differences in viral proteins, 
such as Tat, Rev and RT. Amino acid sequence variation in the viral proteins of various HIV-
1 subtypes can affect virus replication and virulence133. For example, the RT from subtype 
C isolates differs from subtype B by ~7–10%, which can affect drug susceptibility and cause 
drug resistance133. Tat proteins from different subtypes can vary up to 40% without 
significantly affecting Tat transactivation ability134, but the effects on alternative functions of 
Tat135 have not been studied in detail.  
To date, Nullbasic antiviral activity has only been tested against HIV-1 subtype B strains 
such as HIV-1NL4314,15. However, subtype B strains only accounts for ~10% of HIV-1 
infections globally and HIV-1 Tat sequences vary between subtypes, especially for subtype 
C, which is responsible for ~50% HIV-1 infection worldwide136,137. Subtype C is predominant 
in sub-Saharan Africa, India and South America75, while subtype D and recombinant A/D 
are increasing in sub-Saharan Africa20,138. Whether sequence variations in different HIV-1 
subtypes alter the antiviral effect of Nullbasic has not been examined. These differences 
could influence the ability of Tat to interact with RNA and cellular proteins and thus could 
affect the antiviral activity of Nullbasic. Therefore, in this study, the ability of Nullbasic to 
inhibit replication of HIV-1 strains from different subtypes, including subtypes C, D and A/D 
recombinant, was evaluated.  
In this study, we examined Nullbasic antiviral activity against those HIV-1 strains in TZM-bl 
cell line as well as in primary CD4+ T lymphocytes. To enable protein expression detection 
in targeted cells, Nullbasic was tested in the form of fusion proteins as Nullbasic-mCherry 
(NB-mCh) and Nullbasic-ZSGreen1 (NB-ZSG1). The NB-mCH and NB-ZSG1 genes were 
delivered to TZM-bl cell lines and primary CD4+ T cells by a gammaretroviral vector.  Our 
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results show that Nullbasic inhibited replication of the HIV-1 strains tested in both cell lines 
and primary cells. 
3.2 Materials and Methods 
3.2.1 Cell lines and cultures 
HEK 293T(ATCC), TZM-bl139,140 and Phoenix-Ampho141  cell lines were grown in Dubelcco’s 
modified Eagle’s medium (DMEM; Life Technologies) supplemented with 10% (v/v) fetal 
bovine serum (FBS), penicillin (100 IU/ml) and streptomycin (100 µg/ml) (referred to as 
DF10 medium). TZM-bl expressing NB-mCh and mCh cell lines were established by 
transduction of NB-mCh and mCh gammaretroviral virus like particles (VLPs) respectively 
and then selected by FACS for the top 10% of mCherry positive cells by mean of fluorescent 
intensity (MFI). 
3.2.2 Plasmids constructs 
pSRS11-SF-C-EGFP was obtained from Axel Schambach and Christopher Baum142. 
pSRS11 -SF-C-NB-mCh, pSRS11-SF- C-mCh, pSRS11-SF-C-NB-ZSG1 and pSRS11-
SF-C-ZSG1 constructs were made by replacing EGFP in pSRS11-SF-C-EGFP with NB-
mCh, mCh, NB-ZSG1 and ZSG1 respectively.  A proviral plasmid pGCH (GenBank 
accession number AF324493)  was previously described to make HIV-1NL4316. The proviral 
plasmid pZAC (GenBank accession number JN188292.1) was obtained from Jochen 
Bodem143. The proviral plasmids pELI and pMAL (Los Alamos accession number A07108 
and A07116 respectively) were provided by Damian Purcell144. The exon tat genes with HA 
epitope were synthesized by GenScript and ligated into pcDNA3.1+ plasmid (Thermofisher 
Scientific). 
3.2.3 HIV-1 and VLP production 
HIV-1 subtype B, C, D and A/D recombinants were produced from pGCH, pZAC, pELI and 
pMAL proviral plasmids respectively. HEK 293T cells were grown on a 10 cm plate at ~80% 
confluency and transfected with 10 µg of each proviral plasmid, then incubated for 24h at 
37 °C. On the next day, the transfected cells were washed with 1 x phosphate buffered 
saline (PBS) and the DF10 media was replaced.  The supernatant containing HIV-1 VLPs 
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was collected 48 and 72 hours post transfection and the amount of CA in each supernatant 
was measured by ELISA (Zeptometrix), as recommended by the manufacturer. 
NB-mCh or mCh or NB-ZSG1 or ZSG1 VLPs were produced in Phoenix-amphotropic 
retroviral packaging producer cell line by cotransfection of 7.5 µg of SRS11-SF-γC vector 
expressing NB-mCh or mCh or NB-ZSG1 or ZSG1 and 1.5 µg of Gag-Pol expressing 
plasmid using 9µl X-tremeGENETM DNA transfection reagent (Roche) in a 10 cm plate. Six 
hours post transfection, the cells were gently washed with PBS and the media was replaced. 
The VLPs were collected 48 and 72 hours post transfection and filtered through a 0.45 µm 
filter. 
3.2.4 Western blot analysis 
Cell lysates were made from 5  106 NB-mCh or mCh-TZM-bl cell lines in cell lysis buffer 
(50 mM Tris HCl pH 7.4, 150 mM NaCl, 1 mM EDTA and 1% (v/v) Triton X-100). The total 
protein concentration was measured by a Bradford assay using Bio Rad protein assay (Bio 
Rad) and equivalent amounts of protein were used for analysis. The blot was stained with 
anti α-mCherry rabbit antibody (BioVision) followed by anti-rabbit IgG HRP-linked antibody 
(Cell Signaling Technology) and β-tubulin antibody (Sigma Aldrich) followed by anti-mouse 
IgG HRP-linked antibodies (Cell Signaling Technology). 
3.2.5 Transactivation assay 
Tissue culture dishes (6 cm) were seeded with 5  105 TZM-bl cells expressing NB-mCh or 
mCh and then co-transfected with 1 µg of each subtype Tat plasmid and 150 ng of Gaussia 
luciferase expression plasmid. After 48 hours, the cells were washed with PBS and cell 
lysates were made using Glo Lysis buffer (Promega). Luciferase assays were performed in 
96-well white polystyrene microplates, as per the manufacturer’s instructions, using 10 µl of 
the cell lysates and Dual-Glo® luciferase substrate (Promega).  Luciferase activity in each 
sample was measured within 20 minutes by using a luminescence microplate reader and 
relative values were normalized to Gaussia luminescence in the sample.  
Next, 3  105  of non-transduced (NT) TZM-bl cells or TZM-bl cells expressing NB-mCh or 
mCh were seeded in 6-well plates. The next day, the cells were infected with HIV-1NL4-3 
(subtype B) or HIV-1ZAC (subtype C)143 orHIV-1ELI (subtype D) or HIV-1MAL (recombinant A/D 
subtype) virus supernatant containing 20 ng CA for 48 hours. The cells were washed with 
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PBS and then cell lysates were made using Glo Lysis buffer (Promega).  Luciferase activity 
was measured as described above.  
3.2.6 Transduction of NB-ZSG1 or ZSG1 VLPs in CD4+ T cells 
Primary CD4+ T cells were purified from PBMCs that were isolated from healthy donor’s 
buffy coat. The CD4+ cells purity was determined by flow cytometry using anti-human CD4 
antibody. The purified CD4+ T cells were then stimulated using human CD3 and CD28 
antibodies for 48 hours. NB-ZSG1 or ZSG1 VLPs were concentrated using the precipitation 
method, through the addition of 20% (v/v) of 34% polyethylene glycol 8000 (Sigma Aldrich) 
and 10% (v/v) of 0.3M sodium chloride solution.  The solution mixture was incubated at 4 °C 
for 1.5 hours, mixed every 30 minutes and then centrifuged at 1500  g for 1 hour at 10 °C. 
The supernatant was discarded and the precipitate was resuspended in 600 µl RF20 IL-2 
medium. The concentrated VLPs (150 µl) were added to Retronectin (Takara) coated 24-
well plate and incubated at 37 °C for 30 minutes. 5  105 stimulated CD4+ T cells were added 
to each well and incubated for 3 days. Transduced cells were processed by FACS to collect 
ZSG1 positive cells, which were grown for 3 more days. The RF20-IL2 media was replaced 
every day. 
3.2.7 Infection of HIV-1NL4-3 (subtype B), HIV-1ZAC (subtype C), HIV-1ELI (subtype D) 
and HIV-1MAL (A/D recombinant subtype) in TZM-bl cell lines and primary CD4+ T cells 
NT TZM-bl cells or TZM-bl cells expressing NB-mCh or mCh (3  105 cells/well) cultured in 
6-well culture dishes were infected with a virus stock containing 20 ng CA of HIV-1NL4-3, HIV-
1ELI and HIV-1MAL or 40 ng CA of HIV-1ZAC for 2 hours at 37 °C. A larger amount of HIV-1ZAC 
was required to yield measurable infections. The virus was then removed by washing 3 
times with PBS and the infected cells were cultured at 37 °C with 5% of CO2. The culture 
supernatants were sampled on day 3 and 5 post infection. The amount of HIV CA present 
was measured using a CAp24 ELISA kit (Zeptometrix) according to the manufacturer’s 
instruction. 
Stimulated primary CD4+ T cells (5  105 NB-ZSG1 or ZSG1 or NT) were infected with virus 
stocks containing 2 ng CA of each HIV-1 subtype for 2 hours at 37 °C.  After infection, the 
cells were washed with PBS and cultured in RF20 IL-2 medium.  Cell and supernatant 
samples were collected on days 0, 3, 7, 10 and 14 by centrifugation at 500  g for 5 minutes. 
The amount of viral CA in the supernatant was measured by ELISA. The cells were fixed 
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with 1% paraformaldehyde in PBS solution and NB-ZSG1 or ZSG1 expression was 
measured by flow cytometry. 
3.2.8 Cytotoxicity assays 
Cell metabolic activity was measured by MTS using a CellTiter 96® aqueous one solution 
cell proliferation reagent (Promega) according to the manufacturer’s instructions. Cell 
proliferation was quantified using a Violet Proliferation Dye 450 (BD HorizonTM) assay in 
accordance with the manufacturer’s instructions, and violet fluorescence was measured 
using a violet laser-equipped BD LSRFortessaTM IV flow cytometer.  Apoptosis events were 
quantified using a PE Annexin V apoptosis detection kit (BD PharmingenTM), as per the 
manufacturer’s instructions.  Camptothecin (Sigma Aldrich), which strongly induces 
apoptosis in CD4+ T cells, was used as a positive control.  
3.2.9 Statistical analysis 
Mean values of percentage of transactivation inhibition between strains were compared 
using Kruskal-Wallis one-way analysis of variance. A 95% confidence interval was used, 
therefore a p value less than 0.05 was considered to be significant. 
3.3 Results 
3.3.1 Inhibition of  transactivation and replication of diverse HIV-1 subtypes in     
TZM-bl cells by Nullbasic-mCherry (NB-mCh) fusion protein 
A schematic diagram of Nullbasic protein and the basic domain mutations (amino acids 49-
57) to glycine and an alanine are shown in Figure 3-1 (a).  A NB-mCh fusion protein, used 
previously to investigate Nullbasic inhibition on HIV-1 Rev activity3, was inserted into a SIN 
gammaretroviral vector SRS11-SF-C (Fig. 3-1b)142. VLPs produced in Phoenix 
amphotropic packaging cells145 were used to transduce TZM-bl cells and those stably 
expressing NB-mCh or mCh, respectively, were collected by FACS. Expression of NB-mCh 
and mCh was confirmed by flow cytometry analysis of the purified cells (Fig. 3-1c) and 
Western blot analysis using an anti-mCherry antibody (Fig. 3-1d). 
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Figure 3-1. Expression of NB-mCh in TZMBL cells 
(a) A schematic of the NB-mCh amino acid sequence. The basic domain of wild type Tat was 
mutated to glycine or alanine residues as shown (green) and other domains are labeled. (b) A 
schematic of SIN gammaretroviral SRS11-SF-C vector showing NB-mCh or mCh expressed by a 
Spleen forming focus virus (SFFV) internal promoter. Rous Sarcoma Virus (RSV) promoter is used 
to transcribe mRNA for packaging in VLPs. The woodchuck hepatitis virus post transcription 
regulatory element (WPRE) was inserted adjacent to the NB-mCh or mCh to enhance the gene 
expression. (c) Purity of selected TZM-bl. TZM-bl cells expressing these proteins were collected by 
FACS, as shown. d. NB-mCh and mCh expression in TZM-bl cells expressing NB-mCh or mCh 
analyzed by flow cytometry. (d). NB-mCh and mCh expression in TZM-bl cells was detected by 
Western blot using anti-mCherry antibody. The blot was also stained using an anti-β tubulin antibody. 
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It is worth reviewing the amino acid sequence heterogeneity of Tat by comparing the 
alignment of Tat proteins from HIV-1NL4-3 (subtype B), HIV-1ZAC (subtype C)143, HIV-1ELI 
(subtype D) and HIV-1MAL (a recombinant A/D subtype). Amino acid substitutions occur in 
all domains except for amino acids 43 to 56 (Fig. 3-2, boxed), which includes a completely 
conserved basic domain. The first 20 residues of each Tat protein include 17 positions that 
are conserved or functionally similar. The carboxyl terminal amino acids 90 to 100 of subtype 
C and D Tat proteins have conserved sequences KKKVE and ETDP (Fig. 3-2, underlined), 
which are also present in Nullbasic (derived from HIV-1BH10). All four Tat proteins maintained 
the cysteine residues in the cysteine-rich domain with one exception; HIV-1ZAC (subtype C) 
has a C31S substitution (Fig. 3-2, blue circled).  
Tat mediates HIV-1 transactivation by binding to TAR RNA in the R region of HIV-1 LTR 
and recruiting P-TEFb49, which in turn binds a super elongation complex (SEC)146,147. P-
TEFb consists of Cyclin T1 and CDK949.  In Tat, K41 is important for intramolecular 
hydrogen bonding and structural integrity of the Tat core48 and is present in all Tat proteins 
shown except in HIV-1ZAC which has T41 (Fig. 3-2, blue circled).  A crystal structure of the 
Tat:P-TEFb complex showed that the surface of 37% amino acids 1–49 are complementary 
to the kinase complex, and this model indicates that the interactions between Tat and P-
TEFb can accommodate substitutions commonly present in different Tat genes48. However, 
Tat interacts with other cellular proteins, many of which are important for HIV transcription, 
for example cyclin-T1, a regulatory subunit of pTEF-b CTD kinase complex148. Therefore, it 
is possible that these subtle differences could affect the ability of Nullbasic to inhibit the 
transactivation by Tat from other HIV-1 strains shown. 
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Figure 3-2. A comparison of the NB amino acid sequence against an amino acid sequence 
alignment for TatBH10, TatNL43, TatZAC, TatELI and TatMAL 
Amino acids shown in yellow are conserved for the Tat variants. TatZAC S31 and T41 residues are 
circled (blue). The basic domain is indicated as a black rectangle. 
To test if transcription by different Tat varieties can be inhibited by Nullbasic, TZM-bl-NB-
mCh and TZM-bl-mCh cell lines stably carrying a HIV-1-LTR firefly luciferase reporter were 
co-transfected with eukaryotic expression plasmids that express either TatBH10, TatZAC, 
TatELI, TatMAL or an empty expression plasmid and a Gaussia luciferase expression plasmid 
Gaussia luciferase is used to control for transfection efficiency. Tat can activate the HIV-1-
LTR firefly luciferase reporter in TZM-bl cell lines, while Gaussia luciferase reporter enables 
linear quantification of relative transfection efficiencies between samples149. The amount of 
firefly luciferase activity present in lysates from the transfected TZM-bl cells was measured 
and the relative luminescence unit (RLU) values were normalized to Gaussia luciferase 
RLUs measured in the culture supernatant. The results show that expression of NB-mCh in 
TZM-bl-NB-mCh cells reduced transactivation of the HIV-1 LTR luciferase reporter in all 
subtypes tested from ~70 to ~90% (Fig. 3-3). The data shown is a representative from two 
independent experiments with similar results, each experiment was carried out in triplicate. 
In future, at least one more set of experiments should be done to confirm the results. 
Although TatZAC showed a trend towards less inhibition than others, this difference did not 
achieve statistical significance. Overall, the level of inhibition observed is similar to that of 
Nullbasic in a previous report15. 
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Figure 3-3. NB-mCh inhibits Tat-mediated transactivation after transfection of TZM-bl by Tat 
variants from different strains  
TZM-bl cell lines expressing NB-mCh or mCh were transfected with pCDNA3.1+ containing each 
Tat variant or with empty Pcdna3.1+. A Gaussia luciferase expression plasmid was co-transfected 
as a control for transfections efficiency. Luciferase activity was measured 48 hours post transfection. 
Bars indicate mean percentage of transactivation inhibition by NB-mCh compared to that of mCh. 
The p value of the data set is shown. Data shown is representative from two independent 
experiments each carried out in triplicate. 
The HIV-1 LTR reporter in TZM-bl cells is based on a subtype B LTR promoter.  Sequence 
alignment of TAR shows variations among the strains, as seen in Figure. 3-4(a), especially 
for MAL TAR, where two deletions occurred and changed the bulge structure.  Predicted 
structures of bulge and stem loop of the TAR RNA shown in Figure 3-4 (b) indicate variations 
of TAR RNA bulge and stem loop structures between different HIV-1 strains. These 
variations could affect TAR RNA function during transactivation by Tat or inhibition of 
transcription by Nullbasic. Consequently, we tested if each subtype-specific proviral 
encoded Tat protein could transactivate the associated proviral HIV-1 LTR promoter in the 
presence or absence of NB-mCh.  
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Figure 3-4. TAR RNA sequence and secondary structure. 
(a) DNA sequences of TARNL43, TARZAC, TARELI and TARMAL. TARMAL: TARMAL has deletions at 
nucleotides 24 and 53, relative to TAR NL43 (circled in purple). Boxes indicate nucleotide 
polymorphisms in each TAR sequence that affect RNA structure stability relative to TAR NL43. 
Similarly, nucleotide changes in the bulge or loop region are indicated by yellow circles. (b) The 
predicted secondary structure determined by Mfold of TARNL43, TARZAC, TARELI and TARMAL: the 
relative free energy (dG) calculated by Mfold for each structure is shown. Tat interacting residues 
are located on the bulge structure, nucleotides 22-24. 
Post infection, the integrated provirus produced Tat that can activate the HIV-1-LTR 
luciferase reporter in TZM-bl cells, which is an indicator of virus infection and replication. To 
evaluate Nullbasic inhibition on Tat-mediated transactivation of different HIV-1 strains, we 
infected TZM-bl-NB-mCh and TZM-bl-mCh cells with HIV-1NL4-3 (subtype B), HIV-1ZAC 
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(subtype C), HIV-1ELI (subtype D) and HIV-1MAL (recombinant A/D subtype) produced in 
HEK293T cells or with mock supernatant. Lysates prepared from HIV-1 infected TZM-bl 
cells 48 hours post infection were assayed for firefly luciferase activity and the results were 
normalized to total protein concentration in the cell lysates. NB-mCh significantly reduced 
the amount of RLUs produced compared to control lysates made from infected TZM-bl-mCh 
cells. HIV-1NL4-3 viral Tat transactivation of the LTR-luciferase reporter was inhibited by 
~97%; slightly lower inhibition of transactivation was measured for all other HIV-1 strains: 
HIV-1ZAC by ~90%, HIV-1ELI by ~89% and HIV-1MAL by 91% (Fig. 3-5). However, difference 
between transactivation inhibition in HIV-1NL43 and other strains did not achieve statistical 
significance. The combined above experiments demonstrate that NB-mCh can inhibit 
transactivation of the TZM-bl LTR reporter by each Tat tested, albeit at a slightly reduced 
level compared to HIV-1NL-43.  
 
Figure 3-5. NB-mCh inhibits Tat-mediated transactivation after infection of TZM-bl by 
different HIV-1 strains from different subtypes 
TZM-bl cell lines expressing NB-mCh or mCh were infected with each HIV-1 strain. Luciferase acivity 
was measured from the cell lysates 48 h post infection and normalized by total protein concentration 
in the samples. Bars indicate mean percentage of transactivation inhibition by NB-mCh compared 
to mCh. Error bars indicate standard deviation of three independent experiments carried out in 
triplicate. The p value of the data set is shown.  
Finally, we tested if the presence of NB-mCh could inhibit viral transactivation and replication 
(rather than assessing effects on the integrated HIV-1 LTR-luciferase reporter in the cell 
lines) of each HIV-1 strain in the TZM-bl cell lines. In this 5-day experiment, detection of CA 
by ELISA requires virus replication. Therefore, TZM-bl-NB-mCh and TZM-bl-mCh cells were 
infected and supernatants were collected on day 3 and 5 post infection, and the amount of 
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CA in each sample was by measured by ELISA. As shown in Figure 3-7 a-d, the data shows 
that each HIV-1 strain replicated in NT TZM-bl and TZM-bl-mCh cells, with an increasing 
level of CA from day 3 to 5.  However, HIV-1 replication of all strains was inhibited in TZM-
bl-NBmCh cells.  Comparing day 5 CA levels by TZM-bl-NB-mCh to TZM-bl-mCh cells show 
the production of HIV-1 CA levels dropped in TZM-bl-NB-mCh by >99% for HIV-1NL43, ~97% 
for HIV-1ZAC, ~98% for HIV-1ELI, and ~97% for HIV-1MAL. The combined results support the 
hypothesis that Nullbasic can inhibit virus replication of all the HIV-1 strains tested in TZM-
bl cells.  
 
Figure 3-6. NB-mCh inhibits virus replication of all the strains tested in TZM-bl cells 
TZM-bl cell lines expressing NB-mCh or mCh or NT were infected with each HIV-1 strain. (a) HIV-
1NL4-3 (subtype B), (b) HIV-1ZAC (subtype C), (c) HIV-1ELI (subtype D) and (d) HIV-1MAL (recombinant 
A/D subtype). On day 3 and 5 post infection, culture supernatant was assayed for HIV-1 CA by 
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ELISA. The experiment was performed in triplicate and mean values and standard deviations are 
shown from two independent experiments. 
3.3.2 Antiviral activity of NB-mCh and Nullbasic-ZsGreen1 (NB-ZSG1) in primary 
CD4+ T cells against 4 HIV-1 subtypes 
To evaluate Nullbasic antiviral activity on primary CD4+ T cells, the cells were transduced 
with SIN-based -retroviral vectors encoding NB-mCh or mCh and sorted by FACS for high 
level expression of the fluorescent proteins. As previous studies using NB-ZSG1 fusion 
protein showed strong antiviral activity against HIV-1NL4-3 on Jurkat cells2,150, here we also 
used ZSGreen1 fluorescent protein fused to Nullbasic. The primary CD4+ T cells were 
transduced with SIN-based -retroviral vectors encoding NB-ZSG1 or ZSG1 and selected 
by FACS at the same level as CD4-NB-mCh or CD4-mCh (Fig. 3-7).  However, it is known 
that mCh is expressed as a monomer while ZSG1 is expressed as a tetramer151. This 
difference could influence the Nullbasic fusion proteins antiviral activity. Thus, we compared 
the antiviral activity of NB-mCh and NB-ZSG1 in primary CD4+ T cells. 
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Figure 3-7. Primary CD4+ T cells transduced by NB-ZSG1 or ZSG1 
(a) Expression of ZSGreen1 in NB-ZSG1 or ZSG1 transduced activated CD4+ T cells under EVOSTM 
cell imaging system before cell sorting. (b) Expression of ZSGreen1 in NB-ZSG1 or ZSG1 
transduced CD4+ T cells by FACS. The cells were selected based on the rectangle gate shown. The 
histograms show the sorted cell population. A representative of at least 6 independent experiments 
is shown. 
44 
 
CD4-NB-mCh, CD4-mCh, CD4-NB-ZSG1, CD4-ZSG1 and NT CD4+ T cells were infected 
with HIV-1NL4-3. The cell supernatants were collected on day 3, 7 and 10, then assayed for 
HIV-1 CA concentration by ELISA. The result suggests that both NB-mCh and NB-ZSG1 
inhibited the virus replication, however, NB-ZSG1 showed ~6 times stronger antiviral activity 
compared to NB-mCh (Fig. 3-8). Therefore, we used ZSG1 fusion proteins to evaluate other 
HIV-1 strains in primary CD4+ T cells. 
 
Figure 3-8. NB-ZSG1 inhibits HIV-1NL4-3 replication stronger than NB-mCh  
Primary CD4+ T cells expressing NB-mCh, NB-ZSG1, mCh, ZSG1 and non-transduced cells were 
infected by HIV-1NL4-3 and HIV-1 CA concentrations were measured from the supernatants on each 
time points shown. The experiment was performed two times in duplicate and mean values and 
standard deviations are shown.  
Next, CD4-NB-ZSG1, CD4-ZSG1 and non-transduced cells NT were infected with each 
HIV-1 strain and virus replication was monitored for 14 days (Fig. 3-9). All HIV-1 strains 
were inhibited, but some strain specific differences were noted. For example, at day 14 post 
infection, CA levels reduced by 90% for HIV-1NL43 and 88% for HIV-1ELI and HIV-1MAL in 
CD4-ZSG1 to CD4-NB-ZSG1 cells, whereas no CA was detected after infection with HIV-
1ZAC. It is worth noting that HIV-1ZAC replicated poorly in CD4+ T cells (Fig. 3-9b). Compared 
to HIV-1NL43, HIV-1 ZAC replication in CD4+ T cells on day 14 post infection was ~100-fold 
lower. A reduced level of HIV-1ZAC replication compared to HIV-1NL4-3 was reported 
previously143. Therefore, this may account for a lack of detectable CA by HIV-1ZAC in CD4-
ZSG1 cells.   
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Figure 3-9.  NB-ZSG1  inhibits  virus  replication  of   all  the  strains  tested  in primary CD4+ 
T cells 
Primary CD4+ T cells expressing NB-ZSG1 or ZSG1 or NT were infected with each HIV-1 strain: (a) 
HIV-1NL4-3 (subtype B); (b) HIV-1ZAC (subtype C); (c) HIV-1ELI (subtype D), and; (d) HIV-1MAL 
(recombinant A/D subtype). The culture supernatant was assayed for CA at 3, 7, 10 and 14 days 
post infection. The experiment was performed in triplicate and culture supernatant from each 
replicate was assayed by ELISA for CA at 3, 7, 10 and 14 days post infection. The mean value and 
standard deviation for each time point are shown. A representative of two identical experiments with 
similar results is shown. 
NB-ZSG1 and ZSG1 expression was monitored in uninfected and HIV-1-infected CD4+ T 
cells by flow cytometry. CD4+ T cell populations were initially collected by FACS so that 
ZSG1 positive cell population was >97%. The percentage of ZSG1 positive cells in the 
population at day 14 ranged from 90% (for HIV-1ELI) to 99% (uninfected CD4+ T cells) in all 
experiments, whereas NB-ZSG1 levels were approximately 82% in uninfected and infected 
CD4+ T cells (Fig. 3-10). NB-ZSG1 expression reported here was significantly higher than 
in previous studies using pGCsamEN vectors, where the percentage of CD4+ T cells 
expressing NB-ZSG1 ranged between 40 and 50% of cell populations14.  
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Figure 3-10. A temporal analysis of NB-ZSG1 or ZSG1 expressed in CD4+ T cells 
A temporal analysis of NB-ZSG1 or ZSG1 expressed in CD4+ T cells. Primary CD4+ T cells 
expressing NB-ZSG1 or ZSG1 or NT were infected with each HIV-1 strain: (a) HIV-1NL4-3 (subtype 
B), (b) HIV-1ZAC (subtype C), (c) HIV-1ELI (subtype D), (d) HIV-1MAL (recombinant A/D subtype), 
and (e) uninfected. The level of NB-ZSG1 or ZSG1 positive cells in the population was monitored by 
flow cytometry on day 3, 7, 10 and 14 post-infection. The experiment was repeated three times with 
similar results and a representative experiment is shown. 
We evaluated MFI at each time point; the results suggest that the fluorescent intensity of 
CD4-NB-ZSG1 cells was lower compared to that of CD4-ZSG1 cells. We also observed that 
the CD4-NB-ZSG1 MFI decreased at a higher rate than CD4-ZSG1 MFI (Fig. 3-12). This 
occurred in all infected or uninfected CD4-NB-ZSG1. 
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Figure 3-11. Higher rate decrease of MFI of CD4-NB-ZSG1 compared to CD4-ZSG1 MFI 
Primary CD4+ T cells expressing NB-ZSG1 or ZSG1 or NT were infected with each HIV-1 strain: (a) 
HIV-1NL4-3 (subtype B), (b) HIV-1ZAC (subtype C), (c) HIV-1ELI (subtype D), (d) HIV-1MAL 
(recombinant A/D subtype), and (e) uninfected. MFI was monitored at each time point indicated. The 
experiment was repeated three times with similar results and a representative experiment is shown. 
We investigated if expression of NB-ZSG1 in CD4+ T cells had a measurable detrimental 
effect that could explain why levels of NB-ZSG1 positive cells declined. First, we evaluated 
cell viability by MTS colorimetric assay. This assay measures cellular metabolism based on 
reduction of MTS by NAD(P)H-dependent oxidoreductase enzymes, largely in the cytosolic 
compartment of dividing cells152,153. No significant difference between CD4-NB-ZSG1 and 
CD4-ZSG1 cells were found, although both NB-ZSG1 and ZSG1 cells had a slightly lower 
metabolic activity than NT cells, suggesting the transduction, cell purification processes or 
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ZSG1 were responsible for the decrease level of NB-ZSG1 positive cells (Fig. 3-11a). 
Second, we measured cell proliferation using a cell permeable and VPD450 dye for 
monitoring of cell division by flow cytometry. No difference in proliferation was observed 
between CD4-NB-ZSG1 and CD4-ZSG1 (Fig. 3-11b). Given that HIV-1 wild type Tat is 
reported to have pro- and anti-apoptotic activities in primary CD4+ T cells154, an Annexin V 
assay was used to determine if NB-ZSG1 expression affected cellular apoptosis. All of the 
cells tested had very little or no apoptosis (Fig. 3-11c). Therefore, we cannot account for a 
drop in NB-ZSG1 levels in CD4+ T cells due to detrimental effects of NB-ZSG1 on the 
cellular pathways tested. However, Nullbasic may affect other cellular pathways other than 
those tested leading to reduced levels of Nullbasic expression in the cells. 
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Figure 3-12. NB-ZSG or ZSG expression does not affect CD4+ T cell viability, proliferation or 
induce apoptosis 
(a) An MTS assay was used to measure the viability of CD4+ T cells expressing NB-ZSG1 or ZSG1 
or NT. (b) The proliferation of CD4+ T cells expressing NB-ZSG1 or ZSG1 or NT was measured 
using VPD450 dye assay. (c) An apoptosis assay using PE Annexin V was used to monitor levels 
of apoptosis in CD4+ T cells expressing NB-ZSG1 or ZSG1 or NT. All assays were performed in 
triplicate and were repeated three times. Mean values and standard deviations are shown. 
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In summary, here we show that Nullbasic can inhibit replication of different HIV-1 strains 
from diverse subtypes. The outcome indicates that the replication pathways affected by 
Nullbasic are most likely shared by these HIV-1 strains.  
3.4 Discussion 
In this study, we investigated if Nullbasic could inhibit viral gene expression and virus 
replication of four different strains representing four HIV-1 subtypes in human cells. We 
previously showed that Nullbasic has three independent antiviral properties at different 
stage of HIV-1 replication cycle15: 1) inhibition of transactivation of virus gene expression by 
HIV-1 Tat2,15,127; 2) inhibition of HIV-1 Rev activity by sequestration of DDX116,18, and; 3) 
binding to HIV-1 reverse transcriptase in the virion, leading to premature uncoating and 
defective reverse transcription in newly infected cells18. Given that Nullbasic inhibits HIV-1 
by binding to both cellular (PTEFb and DDX1) and viral RT targets, we found that NB fusion 
proteins had antiviral activity against all strains tested, although some differences were 
observed. 
Using TZM-bl cells, the effect of Nullbasic on transactivation and virus replication was 
examined in three ways. Briefly, wild type Tat mediates HIV-1 transactivation by binding and 
recruiting the SEC and P-TEFb (composed of Cyclin T1 and CDK9) to nascent viral mRNA, 
where CDK9 can phosphorylate RNAPII, leading to highly processive RNA transcription146 
[32]. A crystal structure of the Tat-P-TEFb complex showed that Tat tightly binds to P-TEFb 
because 37% of its folded N-terminal domain (amino acids 1-49) surface is complementary 
to the kinase48. In Nullbasic, amino acids 1-48 are wild type but amino acids 49-57 are 
mutated. Hence, Nullbasic is able to bind P-TEFb2,16 but cannot recruit the protein complex 
to nascent viral mRNA, which requires the RNA binding function of the Tat basic domain 
(amino acids 49-57)129.   
In TZM-bl transfection experiments where equivalent amounts of each Tat expression 
plasmid were used, the overall inhibition of transactivation had a similar range (70-90% 
inhibition) but TatZAC was consistently inhibited the least by NB-mCh. Interestingly, a 
consensus subtype C Tat was reported to have superior transactivation capacity compared 
to a consensus subtype B Tat155, whereas TatZAC was a poor transcriptional activator here 
compared to the other Tat proteins tested. This is probably due to a TatZAC K41T substitution 
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that may affect interaction between TatZAC and Cyclin T1155. TZM-bl cells were infected by 
each HIV-1 strain and transactivation of the TZM-bl LTR-luciferase reporter was inhibited at 
similar levels (~90% inhibition of TatZAC, TatELI and TatMAL).  Furthermore, replication of all 
four viral strains was strongly inhibited by NB-mCh, which ranged from 97-99%. It is 
interesting that NB-mCh inhibited virus replication of each strain better than it inhibited trans 
activation LTR-Luciferase reporter, but the reason for this is yet unclear. This difference 
inhibition level could be due to multiple round of viral infection and replication would amplify 
the blockade by Nullbasic because of additional targets during the replication cycle, such as 
transactivation, RT function and RRE function, while in the transient transfection assay, only 
the transactivation function of Tat would be affected.  Another possibility is differences in 
the TAR RNAs of the various viral strains. Further work will be required to elucidate the 
reasons. The data clearly shows that viral transcription and replication mediated by the four 
different Tat variant proteins, representing different HIV-1 subtypes, was inhibited by NB-
mCh under the conditions tested.  
A previous study used an MLV-based -retroviral vector, pGCsamEN14, containing NB-
ZSG1 or ZSG1 to transduce primary CD4+ T cells. In that study, cells that expressed NB-
ZSG1 significantly delayed HIV-1NL4-3 replication compared to cells expressing ZSG1. 
However, pGCsamEN is not self-inactivating (SIN) and expression of a transgene is via the 
MLV-LTR promoter. Therefore, non-SIN -retroviral vector can be transcriptionally 
repressed in cells. This repression can be anticipated in SIN-based -retroviral vectors that 
used strong constitutively expressed internal promoters. Using this vector, a dramatic loss 
of NB-ZSG1 expression (~50%) was observed in CD4-NB-ZSG1 population by day 7 post 
infection156. Therefore, SIN-based -retroviral vectors, which express transgene via SFFV 
promoter, were used in this study to transduce CD4+ T cells.  
It is interesting that in primary CD4+ T cells, NB-ZSG1 had a stronger antiviral activity than 
NB-mCh. The different levels of the Nullbasic antiviral properties between this two fusion 
protein forms is possibly due to different oligomerization state of the fluorescent proteins 
fused to Nullbasic. mCherry forms a dimer while ZS-Green1 forms a tetramer151, and it is 
possible these multimeric states may cause different protein conformations that can affect 
Nullbasic antiviral activity. Perhaps Nullbasic in mCherry fusion protein forms a dimer while 
in ZS-Green1 fusion protein it forms a tetramer. This result indicates that Nullbasic antiviral 
effect is more pronounced in the form of a tetramer.  A tetramer would bind with higher 
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avidity to its target than a dimer151, and thus could induce aggregation of p-TEFb. Further 
study is required to understand the mechanism behind this. For example, by performing co-
immunoprecipitation assay to examine the strength of interaction between NB-mCh or NB-
ZSG1 and P-TEFb.  
The replication of all HIV-1 strains in stimulated primary CD4+ T cells was also inhibited but 
differences were noted. The replication capacity of HIV-1ZAC was below the limit of detection 
(where an ELISA assay can measure CA as low as ~4 pg/ml), whereas HIV-1NL43 and HIV-
1ELI and HIV-1MAL were strongly inhibited.  
We also noted that although the FACS isolated CD4-NB-ZSG1 and CD4-ZSG1 cells were 
>97% ZSG1 positive, the percentage of ZSG1 positive cells was maintained by CD4-ZSG1 
population over 14 days, whereas the percentage of NB-ZSG1 positive cells in the CD4-NB-
ZSG1 population decreased by about 10-20%. We also observed a higher rate of MFI 
decrease in the CD4-NB-ZSG1 cells compared to that of CD4-ZSG1 cells. However, our 
data indicates that cell proliferation of CD4-NB-ZSG1 and CD4-ZSG1 are similar, and levels 
of cytotoxic effects and apoptotic cells were unchanged. We recently reported that NB-ZSG1 
strongly suppressed HIV-1 transcription in Jurkat cells2, so one possible cause of this NB-
ZSG1 decreased expression level is that NB-ZSG1 also negatively affects transcription by 
the constitutively active SFFV promoter. Given that NB-ZSG1 is able to target P-TEFb, it 
may impede an SEC required for HIV-1 transcription157, and perhaps SEC complexes that 
stimulate transcription by the SFFV promoter. Testing these possibilities will require 
determining if the NB-ZSG disrupts the P-TEFb:SEC complexes, and further understanding 
of transcriptional activation of the SFFV promoter.  
Our data shows HIV-1 replication increased in CD4-NB-ZSG1 cells as the numbers of CD4-
NB-ZSG1 cells decreased, as we observed previously14. It is possible that alternative 
promoters used to express Nullbasic in the retroviral vector may provide sustained 
expression of NB-ZSG1 and lead to a better viral control. In addition, it would be also 
interesting to introduce a Nullbasic-type mutation into other Tat variants and examine if a 
strain-specific custom Nullbasic gene is a better inhibitor of specific strains. 
Overall, SIN-based gammaretroviral vectors improved expression of Nullbasic. The study 
shows that Nullbasic can inhibit replication of different HIV-1 strains from four subtypes in 
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TZM-bl cell line as well as in primary CD4+ T cells. Stable expression of Nulbasic may have 
utility in a future gene therapy approach applicable to genetically diverse HIV-1 strains. 
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CHAPTER 4  
Establishment of an acute HIV-1 Infected Mouse Model to Examine 
Nullbasic Antiviral Activity in vivo 
 
4.1 Introduction 
Nullbasic effects have been extensively studied in vitro in human cell lines as well as in 
primary cells, but the in vivo effects have not been studied. In vitro studies of Nullbasic 
provide evidence about various Nullbasic antiviral mechanisms as well as its efficacy in 
laboratory adapted cell lines and primary CD4+ T cells, but cannot determine if the antiviral 
activity is similar in vivo.  As an advance step towards the application of Nullbasic in gene 
therapy, a preclinical study in an animal model is an important step forward towards an 
eventual trial in humans.  
A humanized mouse model enables studying Nullbasic effects in vivo and can also help in 
understanding the virus reservoir in the body. For the current study, an acute HIV-1 infection 
model was developed using BALB/c-Rag2-/-γc-/- mice. BALB/c-Rag2-/-γc-/- strain has been 
used in previous studies to investigate HIV-1 in vivo123,158. Because this BALB/c-Rag2-/-γc-
/- mouse strain is immunodeficient, it accepts human cell transplantation. This 
immunodeficient mouse strain was developed by mutation of recombination-activating gene 
(rag). Rag gene is conserved in human and mice159. Rag1 and Rag2 proteins play an 
important role in forming an enzyme complex that joins T and B cell receptor genes. Knock 
out of rag gene results in inability to produce mature T and B cells. The rag deficient BALB/c 
mice were not leaky in T and B cell production and less radiosensitive compared to severe-
combined-immunodeficiency (SCID) mice. Therefore, rag model is more susceptible to 
preconditioning by irradiation in order to generate a high rate of engraftment159.  Engraftment 
is a result of transplanted cells homing, adapting and proliferating in the recipient body160. 
However, Rag1 and Rag2 deficient mice generate unwanted NK cells, so mutations of 
common gamma chain receptor (γc) to prevent NK cell maturation were required. A gamma 
chain is an important subunit protein of interleukin receptors, including IL-2, IL-4, IL-7, IL-9, 
IL-15 and IL-21. Nulling the gamma chain prevents IL-2 and IL-7 signaling, and therefore T 
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and B cell development as well as NK cell maturation122. As a result, BALB/c-Rag1-/-γc-/- 
and BALB/c-Rag2-/-γc-/- mice are susceptible to human PBL or HSC transplantation and HIV 
infection. A previous study by Berges and colleagues using this model showed that the 
engrafted cells were susceptible for HIV-1 infection and the infection led to CD4+ T cells 
depletion123.  
To establish a simple animal model to study Nullbasic activity against acute HIV-1 infection, 
the current study transplanted mature human CD4+ cells into BALB/c-Rag2-/-γc-/- mice (Fig 
4-1). As human CD4+ cells are susceptible to HIV-1 infection, our aim in using this model 
was to examine Nullbasic antiviral activity in vivo. 
 
Figure 4-1. Schematic diagram of establishment of an acute HIV-1 infected mouse model 
PBMCs were isolated from human buffy coat and selected for CD4+ cells. The cells were stimulated 
using CD3 and CD28 antibodies, transduced by NB-mCh, mCh, NB-ZSG1 or ZSG1 VLPs and sorted 
by FACS for cells expressing high levels of each fluorescent protein. The cells were then 
transplanted to previously irradiated mice. Two weeks post transplantation, the mice were infected 
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with HIV-1AD8. Samples were taken from the blood, spleen, liver and lung then analyzed for human 
cell engraftment and for viral RNA levels. 
This acute model supports investigation of short-term Nullbasic antiviral effects in vivo and 
provides preliminary data for the development of a long-lasting chronic HIV-1 infection 
model that may be used for testing Nullbasic antiviral effects using human stem cell 
xenograft. 
4.2 Materials Methods 
4.2.1 Cell lines and cultures 
HEK 293T and Phoenix-Ampho141 cell lines were grown in DF10 medium composed of 
Dubelcco’s modified Eagle’s medium (DMEM; Life Technologies) supplemented with 10% 
(v/v) FBS, penicillin (100 IU/ml) and streptomycin (100 µg/ml). PBMCs were isolated from 
healthy donor’s buffy coat supplied by the Australian Red Cross Blood service using Ficoll 
density gradient centrifugation. CD4+ cells were isolated from the PBMCs by using a MACS 
human CD4+ cell isolation kit (Miltenyi Biotec) as per the manufacturer’s instructions. The 
selected cells were grown in 6 cm tissue culture dishes and stimulated using plates pre-
coated with purified anti-human CD3 (clone HIT3a) and anti-human CD28 (clone CD28.2) 
antibodies (BioLegend) in RPMI medium supplemented with 20% (v/v) FBS and 5 ng/ml IL-
2 (hereafter called RF20 IL-2) for 2 days. All cells were grown at 37 °C in humidified 
incubators with 5% CO2. 
4.2.2 Plasmid constructs 
pSRS11-SF-C-EGFP was a gift from Axel Schambach and Christopher Baum142. pSRS11 
SF-C-NB-mCh or pSRS11-SF-C-mCh construct was made by replacing EGFP in 
pSRS11-SF-C-EGFP with NB-mCh or mCh. A proviral plasmid, pAD8, was used to make 
HIV-1AD8. pAD8-1 was obtained from Allison Greenway (Burnet Institute). 
4.2.3 HIV-1 and VLP production 
HIV-1 subtype B strain AD-8 was produced from pAD8-1 proviral plasmid. HEK 293T cells 
were grown on a 10 cm plate at ~80% confluency and transfected with 10 µg of each proviral 
plasmid, then incubated for 24 hours at 37 °C. On the next day, the transfected cells were 
gently washed with 1 x PBS and the DF10 media was replaced. The supernatant containing 
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HIV-1 VLPs was collected 48 and 72 hours post transfection and the amount of CA in each 
supernatant was measured by ELISA (Zeptometrix) as recommended by the manufacturer. 
NB-mCh or mCh or NB-ZSG1 or ZSG1 VLPs were produced in Phoenix-amphotropic 
retroviral packaging producer cell line by co-transfection of 7.5 µg of SRS11-SF-γC vector 
expressing NB-mCh or mCh or NB-ZSG1 or ZSG1 and 1.5 µg of Gag-Pol expressing 
plasmid using X-tremeGENETM DNA transfection reagent (Roche) in a 10 cm plate. Six 
hours post transfection, the cells were washed with PBS and the media was replaced. The 
VLPs were collected 48 and 72 hours post transfection and filtered through a 0.45 µm filter. 
4.2.4 Transduction of NB-mCh or mCh or NB-ZSG1 or ZSG1 VLPs in CD4+ T cells 
NB-mCh or mCh or NB-ZSG1 or ZSG1 VLPs were concentrated using the precipitation 
method by adding 20% (v/v) of 34% polyethylene glycol 8000 (Sigma Aldrich) and 10% (v/v) 
of 0.3 M sodium chloride solution. The solution mixture was incubated at 4 °C for 1.5 hours, 
mixed every 30 minutes and then centrifuged at 1500  g for 1 hour at 10 °C. The 
supernatant was discarded and the precipitate was resuspended in 600 µl RF20 IL-2 
medium. The concentrated VLPs (150 µl) were added to Retronectin (Takara) coated 24 
well plate and incubated at 37 °C for 30 minutes.  For each well, 5  105 stimulated CD4+ 
cells were added and incubated for 3 days. The transduced cells were processed by FACS 
collecting mCh positive cells. The collected cells were grown for a further 3 days. The RF20-
IL2 media was replaced every day. 
4.2.5 Transplantation of of human CD4+ T cells into BALB/c-Rag2-/-γc-/- mice 
BALB/c-Rag2-/-γc-/- mice were obtained from Denise Doolan (QIMR Berghofer Medical 
Research Institute) and bred at QIMR Berghofer animal house. The mice were irradiated 
with a sublethal dose (350 cgγ) then rested for 6 hours. NB-mCh or mCh or NB-ZSG1 or 
ZSG1 transduced or non-transduced human CD4+ T cells were injected intraperitoneally or 
intravenously to the mice. Each mouse required 5 million CD4+ T cells. Every week, the mice 
were monitored for weight loss and scores were recorded for dull/ruffled coat, hunched 
posture, reduced intake of food or water and movement. 
4.2.6 Infection of of HIV-1 to BALB/c-Rag2-/-γc-/- mice 
Two weeks post transplantation, the BALB/c-Rag2-/-γc-/- mice was infected by HIV-1 with a 
concentration of 50 ng or 100 ng CA p24 via intravenous injection. Blood samples (~100 µl) 
58 
 
were collected every two weeks by tail bleeding in a 1.5 ml tube coated with 10% (v/v) of 
0.05 M Na-EDTA. Plasma was separated and frozen at -80 °C.  Blood cells were used for 
flow cytometry. Ten or six weeks post transplantation, the mice were sacrificed. The mice 
were anaesthetized using isoflurane, then blood was collected via heart puncture (~300-500 
µl). Spleen, liver and lung samples were also collected to detect human cell engraftment as 
well as virus reservoirs. Cells were collected from the spleen and lung tissues for flow 
cytometry analysis and HIV-1 RNA quantification. For flow cytometry analysis, the cells were 
stained with CD4-FITC and CD45-APC antibodies.  Half number of the cells were 
suspended in 1 ml Trizol solution containing 5 ng of synthetic Kanamycin RNA and 1 µg of 
poly-A RNA carrier, and then kept at -80 °C for HIV-1 RNA detection.  
4.2.7 Flow cytometry 
Single cell suspensions were prepared from whole blood collected in EDTA pre-coated 
tubes by tail bleeding at weeks 2 and 4, and by heart puncture at week 6. Cells were also 
collected from spleens, livers and lungs. Red blood cells were lysed twice using BD pharm 
lyse buffer (BD Bioscience) for 5 minutes each, centrifuged at 500 x g for 5 minutes at RT, 
washed with 1x PBS, and then stained with anti-human CD4-FITC and anti-human CD45-
APC antibodies (Miltenyi biotec) in the dark at RT for 20 minutes. The cells were then fixed 
with 1% paraformaldehyde and kept in the dark at 4 °C for flow cytometry analysis. At least 
10,000 events in the selected population were collected using LSR Fortessa IV (BD 
Bioscience). The phenotype of engrafted human CD4+ T cell was determined as double 
positive of CD4 and CD45 expressions. Data analysis was performed using Flow Jo 
software version 10.  
4.2.8 Immunohistochemistry 
Spleen and lung samples were collected and fixed in 10% paraformaldehyde. 
Immunohistochemistry was performed using fluorescent multiplex immunohistochemistry 
(mIHC) with tyramide signal amplification protocol by Histology Department of QIMR 
Berghofer Medical Research Institute. The tissues were stained with mouse anti-human 
CD4-CY3 clone 4B12 (Dako) and counterstained with DAPI. 
4.2.9 HIV-1 mRNA isolation and quantification 
HIV-1 replication was evaluated at 4 and 6 weeks post transplantation (2 and 4 weeks post 
infection) by qRT-PCR of the plasma samples. Total RNA was isolated from the plasma 
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using a high pure RNA isolation kit (Roche) as per the manufacturer’s instructions. HIV-1 
RNA was also collected from spleen and lung tissues using Trizol. Synthesis of cDNA was 
performed using Superscript III reverse transcriptase (Thermo Fisher Scientific) as per the 
recommended instructions. HIV-1 RNA quantification was carried out by real time PCR 
using iTaq™ universal SYBR green supermix (Bio-rad). A 5’-LTR sequence 
(GCGACTGGTGAGTACGCCA) was used as a forward primer for HIV-1AD8 strain and an 
LA9 (GACGCTCTCGCACCCATCTCT) was used as reverse primer. PCR cycling condition 
was set as 95 °C for 5 seconds, 65 °C for 15 seconds and 72 °C for seconds using a real 
time PCR detection system (Bio-rad). A synthetic kanamycin resistant RNA cassette 
(Promega) was used as an internal PCR control. 
4.2.1 Statistical analysis 
Data are presented as means plus and minus standard deviation (SD). Mann Whitney non-
parametric analysis was used to compare means between two groups. A confidence interval 
of 95% was used, therefore p value less than 0.05 is considered to be significant. 
4.3 Results 
4.3.1 Intravenous administration provided fast and effective human CD4+ T cell 
engraftment in mice 
Human CD4+ T cells isolated from PBMC of healthy buffy coat donors were column purified 
by positive selection. Flow cytometry analysis shows that 82.5 % of the collected cells are 
lymphocytes (Fig. 4-2, left panel). Monocytes and granulocytes may also present in smaller 
amounts as these cells also express CD4 receptor. The purity of isolated CD4+ T cells was 
99.4% (Fig. 4-2, right panel).  
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Figure 4-2. CD4+ cell purity analyzed by flow cytometry 
CD4+ cells were isolated from PBMC and stained with anti-human CD4 FITC antibody then analyzed 
by flow cytometry. The left panel shows lymphocyte population. CD4+ cells are shown in the 
rectangular gate (right panel).  
We used 8-16 week-old BALB/c-Rag2-/-γ c-/- mice to create an acute HIV-1 infected mouse 
model. For preconditioning, the mice were irradiated at 350 cGy 6 hours before human CD4+ 
T cell transplantation. In developing a humanized mouse model using the BALB/c-Rag2-/-
γc-/- strain, preconditioning of immunodeficient mice is required to increase the expression 
of cell factors required for xenograft engraftment and mouse survival160. Mouse 
preconditioning using a sub lethal total body irradiation technique minimized host versus 
graft disease. It also improved human cell engraftment by inducing proliferative signals of 
the donor cells post cell homing in the recipient.  
For optimization, initially we evaluated the most effective administration route for this model. 
Firstly, 5 million human CD4+ cells were transplanted by intraperitoneal or intravenous 
injection to ten mice per group. Blood samples were then taken at week 4 and 6 post 
transplantation by tail bleeding. The standard method to measure the levels of engraftment 
of human cells in the recipients was performed by flow cytometry analysis of blood samples 
to measure the circulating donor cells160. In this experiment, we stained the cells with anti-
human CD45 and anti-human CD4 antibodies followed by flow cytometry analysis. The 
engraftment level was measured by calculating the number of cells displaying both human 
CD45+ and human CD4+ per ml of mouse blood. The result showed that compared to 
intraperitoneal administration, intravenous administration provided higher engraftment 
levels in the peripheral blood circulation (Fig. 4-3). The difference was statistically significant 
at week 4, but not at week 6. This result suggests that intravenous injection resulted in more 
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reliable human CD4+ T cell engraftment in the mouse. Therefore, we used intravenous 
administration route for further experiments. 
 
 
Figure 4-3. Engraftment of stimulated human CD4+ cells in mouse blood after 
transplantation by intravenous (iv) and intraperitoneal (ip) injections 
Blood cells were collected at time point indicated, stained with anti-human CD4 and anti-human 
CD45 antibodies. The bars indicate mean numbers of human CD4+ and human CD45+ cells per ml 
of mouse blood (N=10). Errror bars indicate standard deviations. 
4.3.2 Engrafted human CD4+ cells can be detected for up to six weeks in mice 
To evaluate the duration of human cell survival in the mouse, the mice were observed for 
ten weeks. Cells recovered from blood samples taken every two weeks, from week 4 to 
week 10 post transplantation, were monitored by flow cytometry. We observed that levels 
of human cell engraftment in the blood samples were the highest at week 6 for most of the 
mice, then the CD4+ cells diminished gradually and were difficult to detect in the blood by 
week 10 (Fig. 4-4). Only 2 mice maintained a detectable level of the human cells in the blood 
by week 10. Therefore, we set week 6 as the end-point for the next experiments.  
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Figure 4-4. Engrafted human CD4+ cells detected in mouse blood 
Blood samples were taken at 4 weeks post transplantation, then every 2 weeks up to week 10. The 
figure shows the number of CD4+ measured by flow cytometry at the time points indicated. 
4.3.3 Human CD4+ cells can be detected in the spleen and lung of mice 
We evaluated the distribution of the human cells in the mouse organs. To detect where the 
human cells were located, the mice were sacrificed at week 6 and cells were collected from 
the mouse organs including spleens, lungs and livers and analysed by flow cytometry. The 
result shows a very modest level of human cell engraftment in the liver, and high levels of 
human CD4+ T cell engraftment were detected in the spleen and lungs (Fig. 4-5).  
 
Figure 4-5. Engraftment of human CD4+ T cells in mouse spleen, lung and liver 
Cells were collected from mouse spleen, lung and liver at 6 weeks post transplantation. The cells 
were stained with anti-human CD4 and anti-human CD45 antibodies. Rectangular gates showed 
cells expressing human CD4 and CD45. The analysis is representative of samples taken from ten 
mice.  
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4.3.4 Efficient transduction and expression of NB-ZSG1, NB-mCh, ZSG1 and mCh in 
CD4+ T cells 
After being stimulated with anti-human CD3 and anti-human CD28 antibodies, selected 
human CD4+ T cells were transduced with SIN gammaretroviral VLP conveying NB-mCh, 
mC, NB-ZSG1 and ZSG1 (Fig. 4-6).  
 
Figure 4-6. A schematic of SIN gammaretroviral SRS11-SF-C vector containing NB-mCh or 
mCh or NB-ZSG1 or ZSG1 
A spleen forming focus virus (SFFV) promoter is used as an internal promoter. Rous Sarcoma Virus 
(RSV) promoter is used to transcribe mRNA for packaging in VLPs. WPRE inserted adjacent to NB-
mCh or mCh orNB-ZSG1 or ZSG1 enhances gene expression. 
The positively transduced cells were selected by FACS. We selected cells that expressed 
high levels of fluorescent protein (Fig. 4-7), because previous studies indicated that 
Nullbasic antiviral activity is dose dependent14,15,18. Therefore, we selected cells that 
expressed Nullbasic fusion proteins or the control fusion proteins above a MFI of 104. The 
transduction rate of NB-mCh or NB-ZSG1 ranged between 10 and 40%, while that of mCh 
or ZSG1 ranged between 20 and 60%.  
 
64 
 
 
Figure 4-7. FACS of transduced CD4+ T cells 
The cells were selected based on the fusion protein MFI above 104 as shown in the rectangular 
gates. The result is representative for at least six experiments. The gate was set based on a previous 
reported study14. 
 
4.3.5 Human CD4+ T cells expressing NB-mCh inhibited HIV-1 replication in vivo, 
partially 
In the next experiment, 5 mice were transplanted by intravenous injection with 5 million of 
either CD4-NB-mCh cells or CD4-mCh cells. Human cell engraftment was monitored after 
week 2 post transplantation. Both NB-mCh and mCh expressing cells were detectable by 
flow cytometry in blood samples at week 4 and 6 post transplantation as well as in the 
spleens and lungs (Fig. 4-8). The data show that there is no significant difference in the 
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levels of engraftment of mice transplanted with CD4-NB-mCh and mice transplanted with 
CD4-mCh. 
 
Figure 4-8. Levels of engrafted cells in blood, spleen and lung samples 
Top: number of engrafted cells per ml of blood in samples taken at week 4 and week 6 post 
transplantation. Bottom: number of engrafted cells per 20 mg of spleen or per 200 mg of lung taken 
at week 6 post transplantation. The mean values and standard deviations from 5 samples are shown. 
To evaluate if the human cells engrafted can support HIV-1 infection, HIV-1AD8, a laboratory 
CCR5 HIV-1 strain of subtype B, was used in this mouse model. HIV-1AD8 uses the CCR5 
chemokine receptor for viral entry to CD4+ cells.  
The mice were injected with a virus stock containing 100 ng of CA (p24) HIV-1AD8 by 
intravenous administration 2 weeks post transplantation. At week 4 post transplantation, 
blood samples were collected from the mice by tail bleeding. At week 6, the mice were 
sacrificed and blood samples were taken from the hearts by heart puncture. To detect HIV-
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1 reservoirs in vivo, we also collected cells from the spleen, lung and liver of mice. Total 
RNA was isolated from the blood plasma as well as from spleen and lung cells. HIV-1 
genomic RNA copy number was measured from the purified RNA samples by qRT-PCR 
using primers specific for full length HIV-1 RNA.  
The level of viral RNA in the infected mice transplanted with CD4-NB-mCh cells was 
compared to that of CD4-mCh transplanted mice. Figure 4-9 shows the qRT-PCR results 
from plasma samples collected at week 4. It shows lower viral RNA levels in the CD4-NB-
mCh transplanted mice compared to CD4-mCh transplanted mice. The mean value was 
~1,800 HIV-1 RNA copies/ml in the former and ~6,200 HIV-1 RNA copies/ml in the later. 
However, by week 6, one of 5 CD4-NB-mCh mice showed increased HIV-1 RNA copies in 
the plasma. We also noted that HIV-1 RNA was detected in the spleen and lung tissues at 
week 6. However, there was no significant difference between HIV-1 RNA in the mice 
transplanted with CD4-NB-mCh and mice transplanted with CD4-mCh, indicating that NB-
mCh antiviral activity in the spleen and lung was not effective at week 6.  
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Figure 4-9. Levels of viremia in week 4 and week 6  
Top: HIV-1 mRNA copy number per ml plasma at week 4 and week 6. Bottom: HIV-1 mRNA copy 
number per 10,000 spleen or lung cells on week 6. The mean values and standard deviations from 
five samples are shown. 
We compared week 4 and week 6 blood samples to determine if Nullbasic antiviral activity 
decreased by time in this in vivo experiment. The result indicates that there was no 
difference of the viral load between week 4 and week 6 blood samples in both NB-mCh and 
mCh transplanted mice (Fig. 4-9). This means Nullbasic retained its antiviral activity from 
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week 4 to week 6. When we compared the viremia levels in NB-mCh or mCh transplanted 
mice at week 4 and week 6, no significant difference was observed. 
 
Figure 4-10. Levels of viremia in NB-mCh and mCh  
  
Left panel: HIV-1 mRNA copy number per ml plasma in NB-mCh transplanted mice at week 4 and 
week 6. Right panel: HIV-1 mRNA copy number per ml plasma in mCh transplanted mice at week 4 
and week 6. The mean values and standard deviations from five samples are shown. The mean 
differences were analyzed by t-test. 
Subsequently, in chapter 3, we observed that NB-ZSG1 antiviral activity against HIV-1NL4-3 
in primary CD4+ T cells in vitro was greater than NB-mCh by ~6 fold. This finding drove a 
change in our mouse model. Based on that result, we performed further experiments by 
transplanting CD4-NB-ZSG1 cells instead of CD4-NB-mCh in mice. 
4.3.6 Human CD4+ T cells expressing NB-ZSG1 inhibited HIV-1 replication in vivo, 
better 
To evaluate antiviral activity of NB-ZSG1 in vivo, human CD4+ T cells isolated from PBMC 
were stimulated with anti-human CD3 and anti-human CD28 antibodies and transduced with 
NB-ZSG1 or ZSG1 VLPs. The transduced cells were selected by FACS for cell expressing 
high levels of NB-ZSG1 or ZSG1. The cells were grown for three days and then transplanted 
to irradiated mice intravenously. Four transplanted NB-ZSG1 or ZSG1 mice were infected 
with HIV-1AD8 at week 2 post transplantation. Two transplanted NB-ZSG1 or ZSG1 mice 
were used as uninfected control. As in previous experiments, we observed human cell 
engraftment at weeks 2, 4 and 6 by flow cytometry. Figure 4-10 shows human cell 
engraftment in blood samples collected at week 6 and engrafted cells numbers are 
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quantified in Figure 4-11. Similarly, human CD4+ T cell engraftment was also detected by 
flow cytometry in the tissue and spleen tissues (see appendix 1 and appendix 2).  
Figure 4-12 shows levels of human cell engraftment in the blood samples at week 4 and 6 
as well as in the spleen and lung tissues. The data suggest that in the blood of infected 
mice, the number of CD4-NB-ZSG1 cells are greater than CD4-ZSG1 cells in both week 4 
and 6 samples. At week 6, the two uninfected CD4-ZSG1 mice show higher number of 
human CD4+ T cells compared to the infected CD4-ZSG1 mice. It is indicative that the 
number of human cells detected in spleen and lung tissues is higher in CD4-NB-ZSG1 
transplanted mice than in CD4-ZSG1 transplanted mice. However, a larger set of mice is 
required to achieve significant values in order to confirm this result.  
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Figure 4-11. Analysis of human CD4-NB-ZSG1 and CD4-ZSG1 cell engraftment in blood 
sample taken at week 6 post transplantation 
Blood cells were stained with anti-human CD4 and anti-human CD45 antibodies and analyzed by 
flow cytometry. Cells stained by both antibodies, double positives, are shown in the oval gates. The 
histograms show MFI for the fluorescent protein. The result is representative of four samples in each 
group. 
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Figure 4-12. Levels of engrafted cells in blood, spleen and lung samples 
Top: number of engrafted CD4+ T cells in ml blood samples at week 4 and week 6. Bottom: number 
of engrafted CD4+ T cells per 20 µg spleen and per 200 µg lung at week 6. Mean values and standard 
deviations from four samples are shown. 
To confirm the human cell engraftment in spleen and lung tissues of the mice, we performed 
immunohistochemistry on samples taken at week 6 and stained with anti-human CD4-CY3 
antibody followed by DAPI as a negative control. The results show that CD4+ cells were 
present in the spleen and lung tissues in both CD4-NB-ZSG1 or CD4-ZSG1 transplanted 
mice indicated by green fluorescence. As mock controls, spleen and lung tissues of non-
transplanted mice were shown (Fig. 4-12 and 4-13). 
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Figure 4-13. Human CD4+ T cell engraftment in spleen tissues 
Spleen tissues were collected and subjected to immunostaining with anti-human CD4-CY3 antibody 
(green). The tissues were also stained with DAPI (blue). Non-transplanted mouse spleen was used 
as mock control. 
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Figure 4-14. Human CD4+ T cell engraftment in lung tissues 
Lung tissues were collected and subjected to immunostaining with anti-human CD4-CY3 antibody 
(green). The tissues were also stained with DAPI (blue). Non-transplanted mouse lung was used as 
mock control. 
HIV-1 RNA levels were measured in the plasma and tissue of all mice at week 4 and 6. We 
observed that the HIV-1 RNA copies were not detected by qRT-PCR in week 4 plasma 
samples, but at week 6 high levels of HIV-1 mRNA were detected (Fig. 4-15) in three of four 
CD4-ZSG1 mice. In three of four CD4-NBZSG1 mice infected with HIV-1AD8, the levels of 
HIV-1 RNA were undetectable, suggesting that NB-ZSG1 inhibited HIV-1 replication. 
However, one CD4-NB-ZSG1 transplanted mouse had measurable level of HIV-1 RNA in 
plasma, spleen and lung samples. Additional sets of HIV-1-infected mice transplanted with 
CD4-NB-ZSG1 and CD4-ZSG1 cells will be required to determine if the reduced levels of 
viral RNA measured is significant, but the preliminary results are encouraging. As Nullbasic 
has not been tested in animal previously, it is not possible to assume the effect size or 
standard deviation, and therefore the sample size can be calculated based on resource 
equation method161. 
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Using this method, a degree of freedom of analysis of variance (ANOVA) or 𝐸 value is 
measured. The 𝐸 value is calculated as follow, and the value should be in the range of 10 
to 20. 
𝐸 = 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑖𝑐𝑒 − 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑔𝑟𝑜𝑢𝑝𝑠 
To see the difference between Nullbasic and control treatments (2 groups), at least 6 
animals per group or 12 animals in total is required to achieve the minimimum E value 10. 
𝐸 = 12 − 2 
𝐸 = 10 
In this study, the sample number was limited to 4 per group because not all the transplanted 
animals showed detectable human CD4+ T cell engraftment by week 4 post transplantation. 
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Figure 4-15. Preliminary results showing levels of HIV-1 RNA in week 6 samples post 
transplantation 
Top panel: HIV-1 RNA copy number in plasma samples collected at week 6. Bottom panels: HIV-1 
RNA copy number per 10000 cells in spleen and lung tissue taken at week 6. Mean values and 
standard deviation are shown for four samples. 
In summary, transplantation of human CD4+ T cells by intravenous injection in BALB/c-
Rag2-/-γc-/- mice resulted in engraftment of the human CD4+ T cells in the mice. Because of 
fast cell reconstitution in the mice and readily available CD4+ T cells, this humanized model 
can be used for understanding antiviral activity of Nullbasic in vivo against an acute HIV-1 
infection. The preliminary results indicate that NB-ZSG1 should undergo further testing 
given the encouraging results indicating that HIV-1 replication was inhibited. 
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4.4 Discussion 
In this study, we established a mouse model that can be used to test Nullbasic antiviral 
activity against an acute HIV-1 infection. An acute HIV-1 infection is defined as the early 
stage of HIV-1 infection that usually presents between two and twelve weeks after exposure, 
when the virus is replicating at rapid rate. At this stage, the virus is highly transmissible162. 
Previous studies have reported that early treatment is beneficial to prevent virus replication 
and spread163. Therefore, it is important to treat HIV-1 during the acute stage to prevent 
virus spread and further disease progression such as chronic infection that may lead to 
AIDS.  
We used isolated CD4+ T cells as donor cells in the BALB/c-Rag2-/-γc-/- mice instead of 
using whole PBMCs, as in previously reported studies164,165. This was done to ensure that 
the vast majority of CD4+ T cell transplanted were transduced and expressed NB-ZSG1 at 
a high level. It has been reported that Nullbasic can potently inhibit HIV-1 replication in 
Jurkat cells2. However in primary CD4+ T cells, the virus is able to replicate if Nullbasic 
expression is too low14. This observation is in agreement with the report that Nullbasic 
inhibits HIV-1 in a dose dependent manner14,15,18. So, in this study we used an improved 
SIN gammaretroviral vector that is able to express genes using the SFFV promoter. The 
transduced cells were selected by FACS where NB-ZSG1 expression was high. Our 
preliminary data indicates that these CD4-NB-mCh and CD4-NB-ZSG1 cells can arrest HIV-
1 replication in the short term. The preliminary data also indicates that NB-ZSG1 is a better 
HIV-1 inhibitor compared to NB-mCh. The reason for this is unclear. 
Our results indicate the route of administration is also an important factor for efficient 
delivery of human cells to the mouse. Here we observed that intravenous administration of 
the transplant cells resulted in improved engraftment in the mouse compared to 
intraperitoneal administration. Through intravenous injection, the transplant cells are directly 
available in the blood circulation, while intraperitoneal injection directs the transplant cells 
to the mouse organs such as the lung and spleen, before they appear in the peripheral blood 
circulation166. We observed human cell engraftment and HIV-1 presence in the lung. This 
suggests targeting of administrated cells accumulated in the lung, which is a reported site 
of memory T cells accumulation167,168. 
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After infection, we observed that the number of human cells detected in CD4-NB-ZSG1 
transplanted mice was higher than in CD4-ZSG1 transplanted mice. This difference was 
obvious in blood samples taken at week 4 and 6. Considering higher number of human 
CD4+ T cells in uninfected CD4-ZSG1 compared to infected CD4-ZSG1, particularly at week 
6, it is likely that the HIV-1 infection has caused human CD4+ T cell depletion. However, we 
noticed variations of human cell engraftment levels for each time point in uninfected mice, 
and thus further investigation using a larger set of mice, at least 6 mice per group, is required 
to confirm this result. 
At 6 weeks post transplantation, high levels of HIV-1 RNA were observed in the lungs when 
CD4-NB-mCh was used. As we showed that NB-ZSG1 is expressed at higher levels in CD4+ 
T cells, it is possible that NB-ZSG1 protected cells in the lung better than NB-mCh, but more 
experiments are required to confirm this.  It is interesting to note that studies show that HIV-
1 replication and viremia is favoured in lung tissue. For example, a previous study showed 
HIV-1 viremia in AIDS patients was 7.6-fold higher in the lung compared to the periphery169. 
Another study using bronchoalveolar lavage samples from HIV-1 patients showed residual 
HIV-1 RNA after six months of cART treatment, while viremia levels were undetectable in 
their blood. The persistent cellular HIV-1 reservoir in the lung in this study was correlated 
with a high population of CD4+ lymphocytes in the alveolar compartment. The study also 
observed that most CD4+ lymphocytes in the lung tissue are long-life memory T cells170. In 
our study, the modest level of antiviral activity by NB-mCh in the lung was likely to be 
associated with the decreased level of its expression by week 6 post transplantation.  
Our in vitro experiments discussed in Chapter 3 revealed that NB-ZSG1 provides higher 
levels antiviral activity than NB-mCh. This finding drove changes in our animal model by 
transplanting NB-ZSG1 instead of NB-mCh to the mice. The result indicates NB-ZSG1 
inhibition for HIV-1 replication in 3 of 4 mice up to week 6. This suggests that NB-ZSG1 is a 
stronger antiviral than NB-mCh both in vitro and in vivo.  The reason for this is unknown. It 
might be due differences in protein conformation caused by the fusion partners that affect 
antiviral functions. In addition, these fluorescent proteins require different multimerization 
states in order to fluoresce. ZSG1 fluoresces as a tetrameric protein while mCh fluoresces 
as a monomer151; so it is possible that the multimeric state of the fusion protein could 
somehow influence the antiviral activity of Nullbasic. Other possible reasons include 
difference in protein half-life or their subcellular localisation. All of these possibilities remain 
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to be investigated. The observation is important and suggests that an appropriate fusion 
protein partner will be important to obtain optimal antiviral activity of Nullbasic.  
An ideal animal model for HIV-1 gene therapy should: demonstrate a high level of human 
cell engraftment without triggering host versus graft disease; provide long term and 
continuous production of human CD4+ cells; allow HIV-1 infection; generate human immune 
response, and; show CD4+ cell depletion upon infection171.  The acute model we developed 
is a reasonable first step but it does not provide long term and continuous production of 
human CD4+ T cells. However, it did enable reliable human CD4+ T cells availability in the 
mice and demonstrate a high rate of human CD4+ T cell engraftment. The high degree of 
variation in results between the animals tested means further testing will be required. 
In conclusion, transplantation of human CD4+ T cells in BALB/c-Rag2-/-γc-/- resulted in a 
short term human cell engraftment that was used to study acute HIV-1 infection. High 
expression levels of NB-ZSG are required for antiviral potency against HIV-1 infection in 
vivo. Further study will require larger sets of transplanted animals. Although the retroviral 
vectors used here are very good, a better delivery and improved expression of Nullbasic to 
target cells is desirable in order to provide long term inhibition of HIV-1 replication. To 
improve this model, HIV-1 infection could be performed earlier, for example a week post 
transplantation, because the human CD4+ T cells only survived for 6 weeks in the mice. In 
addition, a more sensitive PCR method is required to be able to detect viral load during early 
infection due to a relatively limited number of human CD4+ T cells in the first 2 weeks post 
transplantation. 
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CHAPTER 5  
Optimization of Nullbasic Lentiviral Virus Like Particle Transduction      
in T Cells 
 
5.1 Introduction 
Gene therapy is a promising option for the treatment of hereditary and acquired diseases. 
Success in gene therapy requires a safe and effective gene delivery system that can provide 
and maintain an adequate level of gene expression.  Viruses are commonly used as vectors 
to transfer the desired genes to the targeted host cells. Retrovirus and lentivirus, members 
of Retroviridae family, have been extensively developed as gene delivery vectors.  
Lentiviral vectors have advantages for delivering genes to target cells. Compared to 
retroviral vectors, which can only transduce dividing cells due to pre-integration complex 
inability to cross the nuclear membrane, lentiviral vectors can transduce non-dividing 
cells172,173. Lentiviral expression systems provide prolonged transgene expression174. Also, 
lentiviral vectors are considered safer than gammaretroviral vectors in term of theirs reduced 
genotoxicity risk175,176. It is also known that gammaretroviral vectors have risks to the host 
due to potential oncogenesis caused by retroviral insertional activation of host genes177. 
Phase 1 and 2 clinical trials using a HIV-1 based lentiviral vector to modify CD4+ T cells 
showed no adverse events following the lymphocyte transplantation. The clinical trials were 
conducted on 65 HIV-1 patients in total and were followed up to 8 years178.  
In Chapter 3 and 4, a SIN gammaretroviral vector was used to deliver the nullbasic gene to 
target cells. Although this vector can transduce primary CD4+ T cells and the transduction 
rate was efficient, Nullbasic fusion protein expressions decreased over time. We previously 
reported that lentiviral vectors expressed Nullbasic in Jurkat cells at stable levels which 
potently inhibited HIV-12. However, as most lentiviral vectors are based on HIV-1, Nullbasic 
is also a potent inhibitor of lentiviral vector transduction in all cell types tested, particularly 
of human primary CD4+ T cells. Therefore, in this chapter we asked if a lentiviral vector 
could be optimized to deliver nullbasic to primary CD4+ T cells. 
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As stated previously, the vast majority of lentiviral systems used today are derived from HIV-
1. An earlier study measured delivery of a Nullbasic-EGFP (NB-EGFP) fusion protein  to 
Jurkat cells by a lentiviral vector called pLOX14. pLOX is a second generation HIV-1-based 
lentiviral vector that can transduced human cells. It is comprised of an Eef1-α promoter and 
was reported to effectively transduce primary cells including T cell lymphocytes. For 
biosafety reasons, this vector has a deletion in the 3’ LTR to prevent generation of 
replication-competent viruses as well as interaction between LTR and internal 
promoter179,180.  The result showed that delivery of the Nullbasic gene by this HIV-1-based 
lentiviral vector was inefficient compared to delivery of a EFGP control gene with the same 
vector (Fig. 5-1)14.  
 
Figure 5-1. Inefficient transduction of Jurkat cells by Nullbasic EGFP (NB-EGFP) VLPs 
The NB-EGFP or EGFP was delivered to Jurkat cells using pLOX lentiviral system. The VLPs were 
transduced in three different CAp24 amounts. Percent of transduced cells was analyzed by flow 
cytometry by measuring positive EGFP cells14.  
Interestingly in that study, production of NB-EGFP VLPs was not overly effected by 
expression of NB-EGFP in the packaging cell line but there was a trend towards slightly 
reduced VLP levels and VLP-associated RNA, which did not attain statistical significant14. 
Nullbasic is packaged in VLP and studies showed that Nullbasic downregulates the VLP 
infectivity by inhibiting HIV-1 reverse transcription14,18. Nullbasic directly binds reverse 
transcriptase and this leads to instability of the reverse transcription complex and decreased 
viral DNA synthesis14,18, and therefore resulted in inefficient transduction of cells by NB-
EGFP VLPs. 
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However, as lentiviral vectors have stable gene expression and the ability to transduce 
quiescent cells, and are safer than retroviral vectors, it is worth exploring for ways to improve 
transduction efficiency of T cell lines and primary CD4+ T cells with lentiviral VLPs conveying 
Nullbasic. To this end, in this study, we investigated if expression of a Tat antagonist or 
overexpression of viral or cellular proteins targeted by Nullbasic could compensate for poor 
lentiviral transduction of T cells. 
As a Tat antagonist agent, we used a humanized Tat2 intrabody (huTat2) protein. An 
intrabody is an intracellularly expressed recombinant antibody fragment that can bind a 
target protein within the cell. This huTat2 protein is highly expressed in eukaryotic cells after 
transduction. Earlier studies have shown that, when delivered to human immune cells with 
gamma-retroviral gene therapy vectors, the huTat2 intrabody can protect cells from HIV-1 
infection, replication and pathogenesis23,93,94. The huTat2 intrabody binds to amino acids +1 
to +19 in the N-terminal proline-rich region of Tat23, which is entirely conserved in the 
Nullbasic protein. The expressed huTat2 should also bind to Nullbasic at the same amino 
acid residues. By binding to Nullbasic protein that is expressed in the VLP producer cells 
but not incorporated in the VLP, huTat2 will prevent Nullbasic inhibitor activity on RT and 
may block inhibition of lentiviral VLP infectivity. 
Acting in a dominant negative manner, Nullbasic inhibits Tat-mediated transactivation by 
binding to P-TEFb, leading to the inhibition of transcription by RNA polymerase II (RNAPII)2. 
Furthermore, Nullbasic inhibits transport of RRE-containing HIV-1 mRNA through direct 
interaction with DDX1, a cellular protein that plays an important role in Rev-mediated 
transport of HIV-1 mRNA from the nucleus to cytoplasm3. These actions may also negatively 
affect transduction efficiencies of HIV-based lentiviral VLPs14.  
Can transduction efficiency of Nullbasic lentiviral VLPs be restored by overexpression of 
important viral or cellular factors? For example, besides Tat main function as a transcription 
enhancer, Tat is also important for optimal HIV-1 reverse transcription128. A previous study 
showed that transfection of wild type Tat expression vectors could rescue defects in reverse 
transcription of HIV-1 with a tat gene deletion128. Interestingly, a subsequent study showed 
that overexpression of Tat in cells having Nullbasic could compensate for decreased HIV-1 
mRNA levels due to Nullbasic inhibition on Rev activity in nucleocytoplasmic transport of 
singly spliced and unspliced HIV-1 genomic RNA3. Furthermore, overexpression of DDX1 
could counteract Nullbasic inhibition on Rev function by rescuing Rev nuclear localization 
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disrupted by Nullbasic3. Here, we hypothesized that overexpression of either wild type HIV-
1 Tat, HIV-1 Rev or the RNA helicase DDX1 may improve transduction efficiency of NB-
ZSG1 VLPs. 
5.2 Materials and Methods 
5.2.1 Cell lines and cultures 
Human embryonic kidney (HEK) 293T cells (ATCC® CRL-3216) were grown in Dubelcco’s 
modified Eagle’s medium (DMEM; Life Technologies) supplemented with 10% (v/v) FBS, 
penicillin (100 IU/ml) and streptomycin (100 µg/ml) (referred to as DF10 medium). Jurkat 
cells were grown in RPMI medium (Life Technologies) supplemented with 10% (v/v) FBS, 
penicillin (100 IU/ml) and streptomycin (100 µg/ml) (referred to as RF10 medium). HEK 
293T-mCh-huTat2 and HEK293T-mCh cell lines were established by transduction of 
pSicoR-Ef1a-mCh-huTat2 and pSicoR-Ef1a-mCh-puro lentiviral systems respectively, and 
were then selected using FACS for the top 10% of mCherry expressing cells by MFI. 
5.2.2 Isolation of of primary CD4+ cells 
Human buffy coat was supplied by Australian Red Cross Blood service (negative for HIV-1, 
hepatitis B and hepatitis C). PBMCs were isolated by Ficoll density gradient centrifugation 
of the buffy coat. CD4+ cells were isolated from the PBMCs by using a MACS human CD4+ 
cell isolation kit (Miltenyi Biotec) according to the manufacturer’s instructions. The selected 
CD4+ cells were grown in 6 cm tissue culture dishes and stimulated using plates pre-coated 
with purified anti-human CD3 (clone HIT3a) and anti-human CD28 (clone CD28.2) 
antibodies (BioLegend) in RPMI medium supplemented with 20% (v/v) FBS and 5 ng/ml IL-
2 (hereafter called RF20 IL-2) for 2 days. All cells were grown at 37 °C in humidified 
incubators with 5% CO2. 
5.2.3 Generation of of plasmid constructs 
A lentiviral transfer plasmid expressing mCherry-T2A-huTat2 (pSicoR-Ef1a-mCh-huTat2) 
was constructed. Briefly, the gene encoding hu-Tat2 was fused at the C terminal of mCherry-
T2A in a pSicoR lentiviral vector using EcoRI and XmaI restriction sites. A huTat2 with C 
terminal HA tag gene, huTat2-HA, was inserted into a pcDNA3.1+ plasmid (Addgene). 
Lentiviral plasmids expressing NB-Flag-ZSG1 or ZSG1 were constructed by inserting the 
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NB-Flag-ZSG1 or ZSG1 genes into a pSicoR vector using NheI and EcoRI restriction sites. 
pNL4-3.Luc.R-E- was obtained through the NIH AIDS Reagent Program, Division of AIDS, 
NIAID, NIH181,182. Tat101 Flag, DDX1-HA and Rev expression plasmids were constructed 
in pcDNA3.1+.  
5.2.4 HIV-1 and VLP production 
VSV-G-pseudotyped HIV-1 harbouring firefly luciferase reporter gene was produced in HEK 
293T cells by co-transfection of pNL4-3.Luc.R-E- and pCMV-VSV-G plasmids for 48 hours. 
The supernatant was collected and CAp24 concentration was measured by ELISA 
(Zeptometrix), as recommended by the manufacturer. 
NB-ZSG1 and ZSG1 VLPs were produced in HEK 293T cells expressing mCherry-T2A-sFv-
Hutat2 or mCherry alone or parental HEK 293T cells in a 10 cm culture disk by 
cotransfection of 2 µg of pSicoR-Flag-NB-ZSG1 or pSicoR-ZSG1 plasmids, 2 µg of pCMV-
VSV-G expressing plasmid and 6 µg of pCMV∆R8.91 plasmid using 10 µl of X-
tremeGENETM  plasmid DNA transfection reagent (Roche) according to the manufacturer’s 
instructions. NB-ZSG1 and ZSG1 VLPs were also produced in HEK 293T cells containing 
overexpression of Tat, DDX1 and Rev by adding 3 µg of each plasmid in the transfected 
solution. Six hours post transfection, the cells were washed with PBS and the media was 
replaced. The VLPs were collected at 48 hours post transfection and filtered through a 0.45 
µm filter. CAp24 concentration was measured by ELISA (Zeptometrix), as recommended by 
the manufacturer. 
5.2.5 Western blot analysis 
Cell lysates were made from the HEK 293T expressing mCherry-T2A-huTat2 or mCherry or 
parental HEK 293T cells in cell lysis buffer (50 mM Tris HCl pH 7.4, 150 mM NaCl, 1 mM 
EDTA and 1% (v/v) Triton X-100). The total protein concentration was measured by a 
Bradford assay using Bio Rad protein assay (Bio Rad) and equivalent amounts of protein 
were used for analysis. To check the mCherry-T2A-huTat2 expression in the cell lines, the 
blot was stained with anti α-mCherry rabbit antibody (BioVision) followed by anti-rabbit IgG 
horseradish peroxidase (HRP)-linked antibody (Cell Signaling Technology) and β-tubulin 
antibody (Sigma Aldrich) followed by anti-mouse IgG HRP-linked antibody (Cell Signaling 
Technology). The expression of Nullbasic, Tat, Rev and DDX1 was confirmed by staining 
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the blot with anti-Tat rabbit (Diatheva), anti-Rev mouse (Santa Cruz Biotechnology) and 
anti-DDX1 rabbit antibodies (Santa Cruz Biotechnology) respectively. 
5.2.6 Transduction of Jurkat cells and primary CD4+ T cells by NB-ZSG1 or ZSG1 
VLPs 
Transduction was performed in 24 well culture dishes using 4 x 105 Jurkat or primary CD4+ 
T cells in each well. For each well, 50 ng VLPs plus 8 ng/ml polybrene were added to the 
cells. Spinoculation was performed by centrifugation at 1500 x g for 1 hour at 32 °C. The 
medium was replaced the next day. Samples were taken at 72 hours post transduction, fixed 
by 1% paraformaldehyde in PBS, and then analyzed by BD LSR 4 flow cytometer. Data was 
analyzed by version 9 FlowJo single cell analysis software.  
5.2.7 Statistical analysis 
Statistical analyses were performed using ANOVA or student t test on the data from at least 
three independent experiments or measurements where p values are shown. A confidence 
interval of 95% was used, therefore p value less than 0.05 is considered to be significant.  
5.3 Results 
5.3.1 An improvement in transduction efficiency with a Nullbasic lentiviral vector 
using an intracellular antibody (intrabody) to Tat 
The gene encoding huTat2 was ligated into the lentiviral vector pSicoR-Ef1a-mCh-puro 
where huTat2 replaced the pac gene encoding puromycin N-acetyl-transferase (PAC) (Fig. 
5-2). In this vector, the expression of mCherry acts as a surrogate marker for huTat2 
expression, which cannot be detected by Western blot analysis as no anti-huTat2 antibody 
is available. A stop codon inserted after a ribosomal skipping gene T2A183 prevented 
translation of PAC in the control vector. The presence of the T2A element in between mCh 
and huTat2 genes prevents translation of a peptide bond between the C-terminal glycine of 
T2A and N-terminal proline of huTat2. Therefore, mCh and huTat2 are expressed as 
separated proteins. 
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Figure 5-2. Schematic of pSicoR vector harbouring PAC and huTat2 Intrabody 
This vector uses cytomegalovirus early immediate promoter (CMVp) hybrid with LTR, cis-acting 
element psi (ψ), RRE and WPRE.  The gene of interest is driven by Ef1α promoter. A ribosomal 
skipping element T2A was inserted in between mCherry and PAC or huTat2. 
VLPs were produced using each vector and used to transduce HEK293T cells. Cells that 
were mCherry positive (Fig. 5-3a) were collected by FACS and the purity was confirmed by 
flow cytometry (Fig. 5-3b). Cell lysates prepared from the selected cells were analyzed by 
Western blot using an anti-mCherry antibody. The mCherry-T2A protein was clearly 
detectable (Fig. 5-3c, middle panel) and serves as a surrogate indicator of hu-Tat2, which 
cannot be detected by Western blot analysis. A low amount of the ~65 kDa mCherry-T2A-
huTat2 fusion protein was observed following longer exposure of the Western blot (Fig. 5-
3c, top panel). A strong mCh band was detected in the mCh-T2A-huTat2 transfected cells 
as a result of ribosomal skipping gene T2A that stopped translation of a specific peptide that 
connects T2A and huTat2. 
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Figure 5-3. MCherry expression in HEK 293T cells. 
(a) HEK293T cells transduced with pSicoR-Ef1a-mCh-T2A-hu-Tat2 or pSicoR-Ef1a-mCh-T2A-puro 
expressed mCherry under EVOS® imaging system. (b). The highly expressed mCherry cells were 
sorted by FACS and analyzed by flow cytometry. (c). mCherry expression in mCh-T2A-hu-Tat2-
Intrabody and mCh-T2A-puro cell lines were detected by Western blot. 
The stable cell line HEK293T-mCh-huTat2 and HEK293T-mCh were infected with HIV-1 
NL4-3.Luc.R-E-181,182 pseudotyped with VSV-G envelope. 24 hours after infection, cell 
lysates were prepared and the level of firefly luciferase was measured. The results showed 
a statistically significant ~25-30% decrease in firefly luciferase activity in HEK293T-mCh-
huTat2 intrabody cells compared to control cells (Fig. 5-4). The data indicate that a Tat-
targeting intrabody can inhibit Tat transactivation of the HIV-1 LTR in HEK293T cells, as 
previously reported in other cell types91.  PSiCoR vector184 was chosen as the preffered 
transduction vector as it uses CMV promoter that can generate strong transgene 
expression.  
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Figure 5-4. HuTat2 intrabody inhibits Tat-mediated transactivation 
HEK293T-mCh-huTat2 and HEK293T-mCh or parental HEK 293T cells were infected by VSV-G 
pseudotype HIV-1 luciferase reporter virus. Bars indicate mean luciferase activity normalized by total 
protein concentrations and error bars indicate standard deviation. Experiments were performed 
three times independently in triplicate. 
The nullbasic gene was fused to ZSGreen1 (NB-ZSG1) and delivered to human T cells 
using a pSicoR lentiviral system (Fig. 5-5). The pSicoR vector has human cytomegalovirus 
immediate early enhancer promoter (CMVp), a strong RNA polymerase II promoter, 
integrated with LTR promoter. NB-ZSG1 or ZSG1 expression is driven by an internal EF1α 
promoter. This transfer vector has central polypurine tract (cPPT) for assisting reverse 
transcription and gene translocation into the nucleus of non-dividing cells, RRE for assisting 
Rev function in transporting mRNA from the nucleus to cytoplasm, and a psi (ψ) packaging 
signal for viral genome packaging. For safety, this vector has an LTR U3 region deletion, 
creating a self-inactivating (SIN) virus that prevents transcription of the full length viral 
genome from LTR post integration. Therefore, this SIN can prevent production of full length 
viral RNA in target cells. A woodchuck hepatitis virus post-transcriptional modification 
element (WPRE) in the vector enhances the level of transgene transcripts in the nucleus 
and cytoplasm of target cells185,186.  
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Figure 5-5. Schematic of three expression plasmids used to generate NB-ZSG1 or ZSG1 
lentiviral VLPs 
The transfer vector, pSicoR, encodes NB-ZSG1 or ZSG1 driven by an Ef1α internal promoter. pCMV 
∆R8.91 was used as a packaging vector and pCMV VSV-G was used as an envelope vector. 
To produce VLPs, this pSicoR vector was co-transfected with a pCMV ∆R8.91 packaging 
plasmid and a VSV-G envelope plasmid in HEK 293 T cells. The packaging plasmid 
construct encodes Gag, Gag-Pol, Tat and Rev to support viral RNA encapsidation, reverse 
transcription and integration in the target cell chromosome. The VSV-G envelope plasmid 
encodes VSV-G envelope that facilitates viral attachment and fusion to target cells.   
Jurkat cells were transduced with equivalent amounts of each VLP normalized to total HIV 
capsid (CA), and with or without a spinoculation. Spinoculation can improve rates of infection 
by retroviruses and transduction efficiency of VLPs187. The cells were transduced and then 
incubated for 72 hours, then the percentage of cells that were positive for ZSG1 or NB-
ZSG1 was measured by flow cytometry. The results showed that >99% of Jurkat cells were 
successfully transduced by ZSG1-VLPs irrespective of spinoculation (Fig. 5-6). This 
suggests that the concentration of ZSG1-VLPs used was saturating for the number of cells 
used. However, at the same concentration of CA, only 12% of Jurkat cells were successfully 
transduced by NB-ZSG1-VLPs without spinoculation (Fig. 5-6a), which increased to 25% 
with spinoculation (Fig. 5-6b). When huTat2 proteins present, the transduction of Jurkat by 
NB-ZSG1-VLPs increased by ~2-fold. With spinoculation, transduction of Jurkat cells by NB-
ZSG1-VLPs improved up to ~2.5-fold when the VLPs were made in HEK293T-mCh-T2A-
huTat2 cells compared to NB-ZSG1-VLPs made in HEK293T-mCh-T2A cells. The 
transduction rate of Jurkat cells by control ZSG1-VLPs was unchanged irrespective of the 
cell line used to make the VLPs. Therefore, we conclude that huTat2 intrabody can 
specifically improve transduction rates of Jurkat cells by NB-ZSG1-VLPs.  
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Figure 5-6. HuTat2 intrabody improved transduction efficiency of Jurkat cells by NB-ZSG1 
lentiviral VLPs 
Jurkat cells were transduced with 50 ng ZSG1 or NB-ZSG1 VLPs produced in VLP producer cell 
lines, as indicated. Transduction was performed using polybrene without spinoculation (a) and with 
spinoculation (b). Bars indicate mean percent of transduced cells and error bars indicate standard 
deviation. Experiments were performed three times independently in triplicate. 
5.3.2 Improved transduction of Jurkat cells by NB-ZSG1-VLPs using cellular or viral 
proteins 
NB-ZSG1-VLPs and ZSG1-VLPs were produced in HEK293T cells by co-transfection of 
pSicoR-Flag-NB-ZSG1 or pSicoR-ZSG1 plasmids, pCMV-VSV-G plasmid and 
pCMV∆R8.91 plasmid along with an empty pCDNA3.1+ plasmid or with plasmids encoding 
Tat, Rev or DDX1.  Western blots were performed using lysates prepared from the 
transfected HEK293T cells to confirm expression of the gene products. The expression of 
NB-ZSG1, Tat, DDX1 and Rev in the VLP producer cells was detected by Western blot (Fig. 
5-7a). The VLPs collected were used to transduce Jurkat cells with or without a 
spinoculation step using an equivalent amount of VLPs normalized to total CA in the 
supernatant.   
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Irrespective of spinoculation, ZSG1-VLPs transduced >99.9% of Jurkat cells under the 
conditions tested (Fig. 5-7b and 5-7c). However, the transduction rate of NB-ZSG1-VLP was 
reduced to ~25% without spinoculation or ~50% with spinoculation, respectively.  
Without spinoculation, the transduction rate was significantly improved when Tat was 
overexpressed in the VLP producer cells but not when DDX1 or Rev were overexpressed 
(Fig. 5-7b). With spinoculation, either Tat or DDX1 overexpression improved the 
transduction efficiency of NB-ZSG1 up to ~70%. Co-expression of Tat and DDX1 
(combined) improved transduction; this was most apparent when spinoculation was used, 
where >95% of Jurkat cells expressed NB-ZSG1.  However, co-expression of Tat, Rev or 
DDX1 had no significant effect on transduction by ZSG1-VLPs (Fig. 5-8). Hence, the results 
indicate that coexpression of Tat and DDX1 together can improve the transduction ability of 
NB-ZSG1 VLPs specifically.  
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Figure 5-7. Tat, DDX1 and Rev improved transduction efficiency of Jurkat cells by NB-ZSG1 
VLPs 
(a) Expression of NB-ZSG1, Tat-FLAG, DDX1 and Rev by Western blot. Lysates were collected from 
the VLP producer cells (HEK 293T cells) and stained with anti-FLAG, anti-Rev, anti-DDX1 and anti 
β tubulin antibodies. (b) Jurkat cells were transduced by VLPs produced in HEK 293T by 
cotransfection of VLP producer plasmids and Tat, Rev and/or DDX1. (c) The same VLPs as (a) were 
used to transduce Jurkat cells by spinoculation. Bars indicate mean percent of transduced cells and 
error bars indicate standard deviation. Mean of each group was compared to mean of NB-ZSG1 
control by t-test. Experiments were performed three times independently in triplicate. 
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Figure 5-8. No effect of overexpression of Tat, DDX1 and Rev to transduction efficiency of 
ZSG1 VLPs to Jurkat cells 
Jurkat cells were transduced with ZSG1 VLPs produced in HEK 293T cells by cotransfection of 
ZSG1 VLP producer plasmids and Tat, DDX1 and Rev plasmids. Transduction was performed by 
spinoculation using polybrene.  Bars indicate mean percent of transduced cells and error bars 
indicate standard deviation. Experiments were performed three times independently in triplicate. 
Mean comparison between groups was analyzed by ANOVA and p value is indicated. 
5.3.3 No improvement in transduction efficiency of NB-ZSG1 VLPs in primary CD4+ 
T cells 
Interestingly, although introduction of Nullbasic antagonist proteins improved transduction 
efficiency of NB-ZSG1 VLPs to Jurkat cells, this method did not help in transducing NB-
ZSG1 to primary CD4+ T cells (Fig.5-9). Hu-Tat2 did not improve transduction of primary 
CD4+ T cells by NB-ZSG1 lentiviral VLPs, and neither did Tat, Rev and DDX1. However, 
ZSG1 VLPs transduced ~50-60% primary CD4+ T cells. This transduction rate increased to 
70% when polybrene was replaced by recombinant human fibronectin (retronectin).  
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Figure 5-9. No improvement in transduction of primary CD4+ T cells by NB-ZSG1 lentiviral 
VLPs 
(a) Primary CD4+ T cells were transduced with ZSG1 or NB-ZSG1 VLPs produced in HEK 293T-
mCH, HEK 293T-mCh-huTat2 and parental HEK 293T cells. Transduction was performed using 
polybrene with spinoculation. (b) Primary CD4+ T cells were transduced with ZSG1 or NB-ZSG1 
VLPs produced in HEK 293T cells by cotransfection of VLP producer plasmids and either Tat, DDX1, 
Rev or combination of Tat and DDX1. Transduction was performed using polybrene with 
spinoculation. (c) The same VLPs as (b) were used to transduce Primary CD4+ T cells using 
retronectin with spinoculation. 
The fact that NB-ZSG1 transduction efficiency in Jurkat cells but not in primary CD4+ T cells 
was improved by adding Nullbasic antagonist agents suggests that difference in cellular 
factor in primary cells compared to Jurkat cells may affect lentiviral transduction. Jurkat and 
primary CD4+ T cells may have different levels of important cellular factors that are required 
during lentivirus transduction.  
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5.4 Discussion 
Lentiviral vectors are useful gene therapy tools for delivering genes of interest into 
mammalian cells. The ability of lentiviral vectors to transfer genes not only to dividing cells 
but also to non-dividing cells and to maintain stable gene expression offers advantages over 
retrovirus vectors. Lentiviral vectors are able to transduce quiescent cells because their pre-
integration complex (PIC) can go through the nucleus membrane173. Furthermore, lentiviral 
vectors are considered to be safer than gammaretroviral vectors because of reduced risks 
of oncogenesis175. 
Nullbasic was delivered to T cells by an HIV-1 derived lentiviral vector called pSicoR. 
However, Nullbasic delivery by this lentiviral vector was hindered by low transduction 
efficiency due to the inhibitory effect of Nullbasic on HIV-1. The fact that Nullbasic inhibits 
reverse transcription causes a shortcoming in the VLP transduction14.  
Nullbasic protein interferes with reverse transcription complex by binding to RT at p51 and 
p66 subunits, affecting the complex stability and causing premature viral uncoating. A 
previous reported study suggests that Nullbasic retains these RT binding determinants. 
18,188. To overcome this problem, we used viral and cellular proteins that act as Nullbasic 
antagonists during VLP production, so that the expressed Nullbasic protein does not bind to 
RT subunits. 
When NB-ZSG1 VLPs were produced in the HEK 293T cell line harboring huTat2 intrabody, 
transduction efficiency in Jurkat cells was approximately twice as high. Transactivation 
assay shows that huTat2 intrabody inhibited Tat-mediated transactivation, indicated by 
decrease of luciferase activity by ~30%. This suggests that hu-Tat2 protein interacts with 
Nullbasic protein expressed during VLP production and inhibits Nullbasic drawback during 
transduction, thereby increasing Nullbasic VLP infectivity in Jurkat cells. Nullbasic protein 
that is not incorporated in the VLP can interact with RT and leads to production of defective 
VLPs. These VLPs may not contain viral mRNAs and therefore are unable to transduce the 
target cells. Hu-Tat2 is likely to bind to Nullbasic at amino acids +1 to +19 in the N-terminal 
proline rich region, as it does to Tat protein. By competitive binding mechanism, hu-Tat2 
can inhibit Nullbasic-RT interaction. To determine the exact mechanism behind this protein-
protein interaction, further studies need to be done, for example by using co-
immunoprecipitation assay. 
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Overexpression of Tat with or without spinoculation may compensate for Nullbasic inhibition 
of NB-ZSG1 VLPs transduction of Jurkat cells. Tat has been shown to enhance reverse 
transcription of HIV-1127,128. Both Tat and Nullbasic bind to reverse transcriptase18,127. Thus, 
we hypothesised that overexpression of Tat might compete for interaction with reverse 
transcriptase and that Tat may partially or completely mitigate Nullbasic negative effect on 
reverse transcription. Our results suggest this hypothesis is possible.  
We hypothesized that transduction efficiency of T cell lines and primary CD4+ T cells may 
be limited to some extent by the availability of full length lentiviral mRNA in the packaging 
cell line. This because we have shown that Nullbasic inhibits Rev that is required for RRE-
directed export of viral mRNA3,16. We showed previously that overexpression of Tat 
reversed Nullbasic interference of Rev3. Likewise, Nullbasic can also interfere with Rev by 
specifically binding DDX1 thus limiting Rev activity, so that overexpression of DDX1 may 
also reduce inhibition of Rev. Similarly, DDX1 together with spinoculation also increased the 
transduction efficiency in Jurkat cells by NB-ZSG1 VLPs. DDX1 is a host cellular protein 
belonging to the ATP-dependent RNA helicase family. This protein assists the HIV-1-Rev-
RRE complex formation by binding to RRE-mRNA, and therefore DDX1 is important in Rev 
function for nuclear transport of singly spliced and unspliced viral mRNA 3. Hence, the 
overexpression of DDX1 compensated for Nullbasic inhibition of the Rev-RRE-NB-
ZSG1mRNA transport from the nucleus to cytoplasm. However, Rev overexpression alone 
was not effective in improving NB-ZSG1 transduction efficiency, suggesting that Nullbasic 
does not interact directly with Rev. This is consistent with the findings of a previous report 
showing direct interaction of Nullbasic with DDX1 but not Rev as a mechanism of Nullbasic 
inhibition of Rev function3. The improvement in the transduction rate of Jurkat cells by NB-
ZSG1 VLPs was more pronounced after the introduction of combined Tat and DDX1 during 
VLP production, suggesting that these proteins have additive effects to counteract Nullbasic 
inhibition of both transcription and viral mRNA nucleocytoplasmic transport. Nevertheless, 
when the same methods were applied to ZSG1 VLPs, there was no significant difference in 
the transduction efficiency of Jurkat cells. This suggests that the effect of huTat2 intrabody, 
Tat and DDX1 on NB-ZSG1 lentiviral VLP transduction efficiency was specific to Nullbasic. 
In our study, we noted that some differences in VLP transduction rates were observed using 
different preparations of VLPs. For example, the transduction rate shown in figure 5-6 was 
about half that shown in figure 5-7. We believe the is due to difference in VSV-G expression 
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in the VLP production cell line, as Gag and Gag-Pol expression were consistent in the VLP 
batches. It is worth noting that irrespective of the VLP batch used, spinoculation increased 
the transduction rate by ~2-fold. 
Spinoculation increased the transduction efficiency of all the tested VLPs in Jurkat cells.  
Spinoculation has a concentrating effect on VLPs.  Also, the centrifugal pressure on the 
cells stimulates actin and cofilin dynamic activity on non-stimulated Jurkat cells.  Actin is a 
protein located in the cell cytoplasm that forms microfilaments as a primary component in 
the cytoskeleton, while cofilin is an actin-binding protein responsible for enhancing the 
treadmilling of actin filaments.  Spinoculation modulates actin and cofilin dynamic activity189.  
VSV-G enveloped virus fusion to target cells is increased by actin filament formation.  
Furthermore, the actin cytoskeleton helps intracellular lentivirus trafficking 190, and thus 
spinoculation improved lentivirus transduction efficiency.  
Although the addition of hu-Tat2 intrabody, Tat, DDX1 and Rev proteins as well as 
spinoculation improved NB-ZSG1 transduction efficiency of Jurkat cells, these methods did 
not help transduction of primary CD4+ T cells with NB-ZSG1 lentiviral VLPs. In contrast, up 
to ~70% transduction efficiency was achieved in primary CD4+ T cells transduced with ZSG1 
VLPs, especially when polybrene was replaced by retronectin. This indicates that lentiviral 
VLPs can transduce primary CD4+ T cells, but not when Nullbasic is present.  These results 
indicate that Nullbasic inhibition of lentivirus was more prominent in primary CD4+ T-cells 
than in Jurkat cells. There are many possible causes for this result, such as cell factor 
differences between Jurkat and primary CD4+ T-cells. Those cells may have different levels 
of important cell factors required during lentiviral vector transduction. One of possible cell 
factors that is different between primary cells and cell lines is eEF1A. eEF1A plays an 
important role during reverse transcription. It is possible that primary CD4+ T cells produce 
less eEF1A proteins compared to Jurkat cells. Lacking eEF1A may cause inefficient reverse 
transcription complex formation188. Further studies are needed to determine different levels 
of eEF1A proteins in these cells, for example using a gradient concentration Western Blot 
from the cell lysates. In future, eEF1A gene could be delivered to the primary CD4+ T cells 
before Nullbasic transduction by using other viral vectors, such as adenovirus based vectors 
to generate transient eEF1A transgene expression in the cells.  
Overall, transduction efficiency of Jurkat cells by Nulbasic lentiviral VLP can be improved 
by the presence of huTat2, Tat and DDX1 together with spinoculation. Therefore, these 
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methods can be used to further study Nullbasic activities and interactions using Jurkat cells. 
However, although lentiviral vectors are preferable delivery system in gene therapy because 
of their ability to transduce non-dividing cells, provide stable transgene expression and have 
less oncogenic risks, we cannot use currently available lentiviral vector to deliver Nullbasic 
to primary CD4+ T cells. The Nullbasic inhibition of lentivirus was so strong in primary CD4+ 
T cells so that addition of Tat, Rev and DDX1 as well as spinoculation method could not 
improve Nullbasic lentiviral VLP transduction efficiency. The next chapter will provide 
conclusion of the thesis, current study limitation and future research direction. 
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CHAPTER 6  
Conclusion 
 
 
This final chapter summarizes the thesis, highlights its findings and contributions, points out 
limitations of the current work, discusses general conclusion of the thesis and outlines 
direction for future research. This chapter is divided into five sections: summary of the thesis, 
contributions of the thesis, limitation, conclusion and future direction. 
6.1 Summary of the thesis 
This research focused on investigation of an antiviral agent that may be used in a gene 
therapy approach. The agent is a mutant of HIV-1 Tat protein, created by substitution of the 
basic domain in the wild type Tat with glycine and alanine residues. Tat basic domain is 
composed of arginine and lysine residues, but is referred to as an arginine rich domain 
(ARD). This ARD is required for Tat to bind TAR RNA during transcriptional activation of the 
HIV-1 LTR promoter. Under biological condition or neutral pH, arginine is a positively 
charged amino acid and therefore has hydrophilic characteristic. Alanine and glycine 
residues have small non-polar aliphatic side chains. Replacing the Tat ARD with alanine 
and glycine residues created Nullbasic and inactivates its ability to recruit pTEFb to the HIV-
1 LTR promoter. Hence, Nullbasic is unable to stimulate HIV-1 transcription. Recent reports 
indicate that Nullbasic can compete with wild type Tat for binding to P-TEFb and this 
accounts for one mechanism by which Nullbasic can inhibit HIV-1 replication. In addition, 
Nullbasic can also inhibit HIV-1 reverse transcription by disrupting reverse transcription 
complex and this requires Nullbasic packaging in the virion during virus production by 
infected cells.  It also inhibits Rev function in transporting HIV-1 mRNA containing an RRE 
from nucleus to cytoplasm.  
Nullbasic antiviral activity against HIV-1 strains from different subtypes was examined in 
Chapter 3. Nullbasic is a mutant Tat of HIV-1BH10, a strain of subtype B, and has so far only 
been tested against other subtype B strains in vitro. In chapter 3 we evaluated if Nullbasic 
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could also inhibit replication of other HIV-1 strains from different subtypes. We tested 
Nullbasic on HIV-1ZAC that represents subtype C, the most prevalence HIV-1 subtype in 
world, HIV-1ELI to represents subtype D that is common in Uganda and HIV-1MAL to represent 
a recombinant form of A/D subtype.   
We generated TZM-bl cell lines expressing NB-mCh or mCh by transduction and FACS 
selection. We observed that Nullbasic strongly inhibits Tat-mediated transactivation of all 
the HIV-1 strains tested both by transfection and infection assays in those TZM-bl cell lines. 
Although both assays resulted in similar inhibition of Tat-mediated transactivation by 
Nullbasic, the assays have small differences. The transfection assay reveals how Nullbasic, 
a subtype B HIV-1 derived Tat mutant, can inhibit Tat isoforms from different strains that 
transactivate an LTR-luciferase reporter stably integrated in the TZM-bl cells. The LTR used 
here is also derived from an HIV-1subtype B strain. The inhibition mechanism will involve 
competition between the wild type Tat variants and Nullbasic in binding P-TEFb.  
In the second transactivation assay, the TZM-bl cell lines were infected with each HIV-1 
strain, so the source of Tat is integrated provirus. In this case Nullbasic could inhibit the 
production of both Tat by the provirus and luciferase production by the LTR-luciferase 
reporter. To some degree, we had expected Nulbasic to be more effective in the second 
scenario, which it was not, as we expected inhibition of Tat expression. Unfortunately, 
Western blots performed to detect Tat post-infection in these experiments were 
inconclusive, as the number of infected cells was too low. 
In a third scenario, the TZM-bl cell lines were infected with the same HIV-1 strains and virus 
replication was monitored by sampling supernatant and measuring CA levels. This system 
adds additional complexity. In this experiment, the transactivation involves a Tat - TAR RNA 
axis of the integrated proviruses and these have subtle difference in the Tat primary 
sequence and TAR RNA stem loop sequence and structure. This is most evident in subtype 
A/D that contains mutations in TAR RNA upper stem loop structure. However, the data 
shows that NB-mCh was an excellent HIV-1 inhibitor under this scenario. 
The replication of all the HIV-1 strains tested was inhibited by Nullbasic both in TZM-bl cell 
lines and primary CD4+ cells. It is interesting to note that even though NB-mCh has a strong 
antiviral activity in TZM-bl cells against the HIV-1 strains, the antiviral activity was lower in 
primary CD4+ T cells compared to that in TZM-bl cell lines. It is possible that differences in 
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cell factors between cell types tested affects Nullbasic antiviral activity. The exact 
mechanisms underlying these differences requires further investigation. However, our 
studies show that NB-ZSG1 has a stronger antiviral activity compared to NB-mCh in primary 
CD4+ T cells, and therefore NB-ZSG1 was used for investigating Nullbasic effects against 
different HIV-1 strains in primary CD4+ T cells.  The results in Chapter 3 demonstrate that 
Nullbasic can inhibit viral replication of all HIV-1 strains tested in primary CD4+ T cells.  
We also observed that NB-ZSG1 showed decreased levels of protein expression over time.  
Because Nullbasic acts in a dose-dependent manner14, when the Nullbasic expression 
levels decrease, the viral load rebounds. We confirmed that expression of Nullbasic in 
primary CD4+ T cells does not alter cell proliferation, viability or induce apoptosis under the 
experiment conditions, and therefore we cannot relate the decrease expression levels of 
Nullbasic to cytotoxic effects.  One of possible reasons for this is the gammaretroviral vector 
we used to deliver Nullbasic to the target cells does not fully support long term and high 
levels expression of transgenes. It is known that expression of retroviral genes is susceptible 
to positional effects and transcriptional silencing that can be influenced by the site of 
integration in the chromosome191. Positional silencing effect have been overcome to some 
degree by chromatin insulators used in retroviral vectors and can block positive and negative 
positional effects at the site of integration when they flank a transgene192-194. New retroviral 
vectors containing chromatin insulators and NB-ZSG1 are in development. 
In Chapter 4, a method to generate an acute HIV-1 infected mouse model was investigated. 
Both intravenous and intraperitoneal administration route to deliver human CD4+ T cells to 
the mice resulted in a profound human cell reconstitution in the mouse peripheral blood 
circulation. However, intravenous delivery through the mouse tails lead to better and more 
reliable human CD4+ T cells engraftment levels detected in peripheral blood. Therefore, the 
intravenous delivery was then selected and implemented to our next experiments. 
HIV-1AD8, a subtype B molecular clone derived from HIV-1AD-87195  and HIV-1SG3.1196, 
was chosen to challenge the humanized mice because this strain utilizes CCR5 chemokine 
receptor to infect human cells. CCR5 receptor is commonly used by HIV-1 to enter human 
cells in early infection.  
We examined if Nullbasic can inhibit HIV-1 replication in vivo. We initiated mouse 
experiments using CD4-NB-mCh cells prior to discovering that NB-ZSG1 had superior 
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antiviral activity compared to NB-mCh. This is because preliminary studies using several 
different cell lines suggested that NB-mCh was an effective HIV-1 inhibitors3,16.  Secondly, 
NB-mCh was selected because some reports suggest that multimeric fluorescent proteins 
had increased cellular toxicity compared to monomeric fluorescent protein197. However, our 
studies showed no detectable toxicity by NB-ZSG1 in human CD4+ T cells and better 
antiviral activity than NB-mCh. Hence, we chose to discontinue CD-NB-mCh transplantation 
experiments in mice. The preliminary results presented in Chapter 4 suggest that CD4-NB-
ZSG1 transplantation model in mice is worth further examination. 
NB-ZSG1 both in vitro and in vivo demonstrated strong antiviral activity in a concentration 
dependent manner14. The level of NB-ZSG1 expressed in transduced cells was selected by 
FACS for cells with a high relative MFI. When the MFI level of CD4-NB-ZSG1 cells 
decreased, the level of viral RNA in samples tended to increase, a threshold level of 
Nullbasic protein is required to inhibit HIV-1 replication, which roughly correlates to a relative 
MFI of > 3.2 × 103 under the condition used. Our preliminary results suggest this is 
achievable in this mouse model for at least 6 weeks. 
In chapter 3 and 4 we used SIN gammaretroviral vector VLPs to efficiently deliver Nullbasic 
to human CD4+ T cells. However, retroviral based vectors are associated with oncogenic 
risks, although this risk has been greatly reduced in modern SIN-based gammaretroviral 
vector designs142. Also, we observed that using this gammaretroviral vector, Nullbasic 
expression levels decreased over time. Interestingly, studies of Nullbasic in Jurkat cells 
showed long term stable expression using third generation lentiviral systems, a pSicoR 
vector2. However, nearly all lentiviral vectors have been derived from HIV-1, which are 
potently inhibited by Nullbasic.  Nullbasic inhibits VLP reverse transcription thus restricting 
transduction. Therefore, in Chapter 5 we tested if the transduction efficiency of NB-ZSG1 
lentiviral VLP could be improved. Using a combination of methods including spinoculation 
and addition of Nullbasic antagonist cellular and viral proteins, we significantly improved 
VLP transduction of Jurkat cells by Nullbasic lentiviral VLPs. To transduce Jurkat cells, 
overexpression of Tat and DDX1 combined with spinoculation method provided the most 
efficient transduction by NB-ZSG1 VLPs. Nevertheless, transducing primary CD4+ T cells 
by Nullbasic lentiviral VLPs remained an intractable problem even by implementing the 
same methods. This could mean that Nullbasic antiviral activity has a stronger effect in 
primary CD4+ T cells compared to Jurkat cells. It is possible that differences in primary CD4+ 
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T cell factors compared to Jurkat cells may be responsible for this outcome. The exact cell 
factors associated with difference in Nullbasic lentiviral VLP transduction efficiency are 
unknown. One of possible cell factors involved in reverse transcription is eEF1A. However, 
further studies are required to determine if Jurkat cells and primary CD4+ T cells produce 
different levels of eEF1A protein. 
6.2 Contributions of the thesis 
This thesis reveals that it is possible to use a mutant of HIV-1 subtype B Tat as an antiviral 
against other HIV-1 subtypes. In this thesis, Nullbasic derived from HIV-1 subtype B Tat can 
act as an antiviral against HIV-1 strains from subtype C, D and recombinant A/D. The reason 
behind this is likely because Nullbasic and Tat sequences from different HIV-1 strains tested 
are conserved. This means that Nullbasic may have a broad antiviral property applicable for 
those HIV-1 subtypes and possibly to other subtypes as well. Therefore, Nullbasic can be a 
potential antiviral agent for future gene therapy for different HIV-1 strains. Nullbasic can 
inhibit Tat variants from different HIV-1 strains because their basic domains are conserved. 
In this study, we observed that Nullbasic inhibited transactivation of four different HIV-1 
strains.  However, the antiviral potency of Nullbasic to other HIV-1 strains should be 
evaluated further.  
This thesis also established a humanized mouse model able to evaluate antiviral potency of 
a mutant Tat protein in vivo against an acute HIV-1 infection. Using human CD4+ T cells 
isolated from healthy donors and transplanted into the mice by intravenous injection, fast 
reconstitution of the human CD4+ T cells in the mouse peripheral blood circulation was 
achieved. Although the human CD4+ T cells were only detected for six weeks in the mouse, 
this mouse model allowed for quick examination of an antiviral agent against an acute HIV-
1 infection. Moreover, this acute mouse model can be used as a basis to further develop a 
humanised mouse model reconstituted with pluripotent CD34+ human cells to examine 
longer term expression and antiviral activity of NB-ZSG1 in vivo. 
Interestingly, in Chapter 3 and 4 we found that different fusion proteins can result in different 
antiviral potency of Nullbasic. When fused to ZSGreen1 fluorescent protein, Nullbasic 
provided a stronger antiviral activity compared to when Nullbasic was fused to mCherry. 
One major difference noted is that ZSGreen1 must form a tetramer to fluoresce, while 
103 
 
mCherry protein will fluoresce as a monomer151. It is possible that these difference 
multimerization state of the fusion protein affects Nullbasic antiviral properties. Differences 
in multimerization status can affect protein conformation and activity, or possibly the protein 
half-life.  It is possible that Nullbasic in the form of tetramer is more stable and has a stronger 
antiviral activity than in the form of monomer. However, further research to test these 
possibilities is required. For example, it would be worth testing if fusion proteins that form in 
different multimeric states also affect Nullbasic antiviral activity. One possibility is using the 
yeast GCN4 leucine zipper domain, which can form dimers, trimers and tetramers, which 
are well characterised198. 
In this thesis, we also developed an effective method to transduce T cells with lentiviral 
based VLP carrying nullbasic gene. A combination of spinoculation method and addition of 
Nullbasic antagonist proteins worked best in transducing Jurkat cells. This is because 
Nullbasic can inhibit HIV-1 reverse transcription and this inhibition effect is similar to HIV-1 
based lentiviral vectors. Unfortunately, those methods did not improve transduction of 
human primary cells as expected. This could mean that Nullbasic inhibition on lentiviral VLP 
reverse transcription is stronger in primary CD4+ T cells compared to T cell lines. To 
overcome this problem, different cell factors involved during VLP transduction of primary 
CD4+ T cells and Jurkat cell lines need to be identified. Genome-wide siRNA screening can 
be performed to identify possible cell factors that inhibit Nullbasic VLP transduction of 
primary CD4+ T cells199. 
We have not seen resistance issues to Nullbasic in this study. However, resistance to 
Nullbasic may be an issue in future, especially when Nullbasic is tested againsts different 
HIV-1 strains with non-conserved Tat sequences. To overcome this, Nullbasic can be 
modified accordingly to fit the Tat sequences from different HIV-1 strains. 
6.3 Limitations of the current study 
In Chapter 3, we tested Nullbasic antiviral activity against four strains from four different 
HIV-1 subtypes, which was a reasonable first step but much more could be tested in the 
future. Therefore, we cannot conclude that Nullbasic can inhibit replication of all HIV-1 
subtypes. It is also possible that some strains of the subtypes could be more resistant to 
Nullbasic than the HIV-1 strains tested.  
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Our results suggest that in primary CD4+ T cells, NB-ZSG1 has a stronger antiviral activity 
than NB-mCh. We compared NB-mCh and NB-ZSG1 against HIV-1NL4-3 strain in primary 
CD4+ T cells. In this thesis, we didn’t examine NB-ZSG1 antiviral activity in TZM-bl cell lines. 
However, the NB-ZSG1 antiviral activity has been tested subsequently in TZM-bl cell lines 
by other colleague in our laboratory in an unpublished report and the result does not indicate 
any significant differences compared to that of NB-mCh.  
In Chapter 4, a method to develop an acute animal model was investigated. We discovered 
that expression of NB-mCh provides a short-term antiviral activity against HIV-1AD8 strain in 
vivo.  We later discovered that NB-ZSG1 provided a stronger and more durable antiviral 
activity than NB-mCh, and therefore we changed from NB-mCh to NB-ZSG1. However, the 
small sample number contributed to a high variability in our results in this study; therefore a 
larger number of animal samples, at least 6 mice per group, is required to confirm the result 
of this study.  
6.4 Conclusion 
Overall, Nullbasic either in the form of fusion protein to mCh or ZSG1 fluorescent proteins 
provided inhibition to HIV-1 replication in vitro and in vivo. The levels of inhibition were more 
profound when Nullbasic protein expressions were maintained at high levels. Using primary 
CD4+ T cells, NB-ZSG1 provided a stronger antiviral activity than NB-mCh against HIV-1NL4-
3 in vitro and HIV-1AD8 in vivo. The in vitro studies of Nullbasic on TZM-bl cell line and primary 
CD4+ T cells also show replication inhibition of HIV-1ZAC (subtype C), HIV-1MAL (subtype D) 
and HIV-1ELI (subtype A/D recombinant).  
Transplantation of human CD4+ T cells to BALB/c-Rag2-/-γc-/- mice resulted in a short-term 
human cell reconstitution and HIV-1 replication in vivo, allowing a study of Nullbasic antiviral 
activity against an acute HIV-1 infection for 4 weeks. It was indicative that NB-ZSG1 can 
provide a stronger and longer antiviral activity in vivo than NB-mCh, but a larger number of 
samples is required to confirm this result. At least 6 animals in each group are required to 
determine statistical significant of Nullbasic effect. 
Although the SIN gammaretroviral vector used in this study was able to deliver Nullbasic 
gene to the targeted cells, the level of expression decreased over time. Therefore, a better 
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viral vector, such as lentiviral vectors to deliver Nullbasic is required. We observed that 
transduction of lentiviral based Nullbasic VLP to Jurkat cells was optimal when Tat and 
DDX1 proteins were present in the VLP producer cells, and the transduction method was 
combined with spinoculation. However, the PSicoR lentiviral vector we used was unable to 
deliver nullbasic-ZsGreen1 gene to primary CD4+ T cells. 
6.5 Future directions 
Investigation of a better vector to deliver Nullbasic to target cells is required. An ideal vector 
for this should provide high levels transgene expression with long term durability. A better 
means of delivering Nullbasic to target cells may result from changing the internal promoter 
of the vector. It is important to choose a promoter that will not be downregulated by Nullbasic 
protein. Towards this goal the lab has identified several constitutively expressed human 
promoters that are not downregulated in the presence of NB-SG1. Another method to 
develop a more stable vector to deliver Nullbasic is to introduce an insulator that can prevent 
silencing of the genes by Nullbasic. An insulator can prevent silencing of viral vectors by 
transgenes192,193. 
Nullbasic interaction with P-TEFb or DDX1 has been previously reported2,3. Nullbasic binds 
to P-TEFb complex but does not initiate transcription2. Nullbasic also binds directly to DDX1, 
causing inhibition of viral mRNA transport by Rev3 from the nucleus to cytoplasm. Nullbasic 
interaction with RT p51 and p66 subunits has been previously revealed by co-
immunoprecipitation18. New lentiviral transduction vectors for primary T cells should have 
the ability to overcome Nullbasic inhibition, for example by mutation of the direct targets of 
Nullbasic such as RT determinant sequences, while retaining the RT functions. 
Another approach that may be beneficial for Nullbasic lentiviral VLP transduction is 
controlling Nullbasic expression in HEK 293 T cells during VLP production by using 
Tetracycline-controlled transcriptional activation system (Tet-off). Nullbasic expression may 
be repressed transiently using this Tet-off technology. As Tetracyclin is highly toxic to 
mammalian cells, its derivatives such as Doxycycline may be used to inhibit Nullbasic 
expression in HEK 293T cells200. 
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NB-ZSG1 showed a stronger antiviral activity compared to NB-mCh in vitro and in vivo. 
Investigation of the mechanism underlying this result is outside the scope of this thesis. It 
could be that by fusion with a tetrameric protein such as ZSG1, Nullbasic forms a tetramer 
as well. MCherry forms a monomer and therefore NB-mCh is possibly available in the cells 
in the form of monomer. This difference multimerization states may affect the antiviral 
activity of Nullbasic as well as its half-life. Further study to discover the mechanism behind 
the greater and longer antiviral activity of NB-ZSG1 compared to NB-mCh is required. 
Additionally, it would be useful to investigate other fusion proteins suitable to for Nullbasic 
detection in future.  Ideally, the proteins are human proteins in order to minimize possible 
off target effect to human cells. 
We noticed that Nullbasic antiviral activity against different strains of HIV-1 from different 
subtypes varied. Since the Nullbasic used in this study was derived from a subtype B HIV-
1 Tat, it would be worthwhile to investigate the antiviral activity of Nullbasic variants derived 
from other subtypes to see if they may provide better antiviral agents specific to each 
subtype. Further testing of Nullbasic antiviral activity against a number of different strains 
from each subtype is required to support the use of Nullbasic against all strains in these 
subtypes. Evaluation of Nullbasic antiviral activity against other HIV-1 subtypes not tested 
in this research is also required to assess the efficacy of Nullbasic as an HIV-1 therapy. In 
addition, in will be beneficial to study the mechanisms by which Nullbasic inhibits reverse 
transcription and Rev function in different HIV-1 strains and subtypes.  
In this thesis, we only tested Nullbasic antiviral activity in vivo against an acute HIV-1 
infection in a very short term. Further study to confirm NB-ZSG1 antiviral activity in vivo 
using a larger number of samples is required. Also, development of a chronic HIV-1 infection 
model is required to study Nullbasic effect against chronic HIV-1 infection. Using stem cell 
transplantation technology, a longer survival of human cells that will allow chronic HIV-1 
infection study in the mice might be achievable.    
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Appendices 
Appendix 1. Analysis of human CD4-NB-ZSG1 and CD4-ZSG1 cell engraftment in lung tissue 
sample taken at week 6 post transplantation 
Cells were stained with anti-human CD4 and anti-human CD45 antibodies and analyzed by flow 
cytometry. Cells stained by both antibodies, double positives, are shown in the oval gates. The 
histograms show MFI for the fluorescent protein. The result is representative of four samples in each 
group. 
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Appendix 2. Analysis of human CD4-NB-ZSG1 and CD4-ZSG1 cell engraftment in spleen 
tissue sample taken at week 6 post transplantation 
Cells were stained with anti-human CD4 and anti-human CD45 antibodies and analyzed by flow 
cytometry. Cells stained by both antibodies, double positives, are shown in the oval gates. The 
histograms show MFI for the fluorescent protein. The result is representative of four samples in each 
group. 
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